,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,192,1,1,,442469,3696,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
1,248,1,1,,442469,3696,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
2,357,2,1,,11111330,3696,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
3,357,2,1,,11111331,3696,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
4,410,1,5,,11111330,3696,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
5,410,1,5,,11111331,3696,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
6,411,2,1,,11111330,3696,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
7,411,2,1,,11111331,3696,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
8,444,1,1,,11111330,3696,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
9,444,1,1,,11111331,3696,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
10,445,3,1,,11111330,3696,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
11,445,3,1,,11111331,3696,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
12,446,1,1,,11111330,3696,Inconclusive,,,,,Stat Signaling Pathway,Confirmatory,,
13,446,1,1,,11111331,3696,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
14,447,1,1,,11111330,3696,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
15,447,1,1,,11111331,3696,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
16,448,1,2,,11111330,3696,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
17,448,1,2,,11111331,3696,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
18,450,1,2,,11111330,3696,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
19,450,1,2,,11111331,3696,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
20,451,1,2,,11111330,3696,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
21,451,1,2,,11111331,3696,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
22,526,1,1,,11111330,3696,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
23,526,1,1,,11111331,3696,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
24,530,1,1,,11111330,3696,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
25,530,1,1,,11111331,3696,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
26,584,1,3,,11111330,3696,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
27,584,1,3,,11111331,3696,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
28,585,1,4,,11111330,3696,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
29,585,1,4,,11111331,3696,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
30,587,1,5,,11111330,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
31,587,1,5,,11111331,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
32,588,1,4,,11111330,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
33,588,1,4,,11111331,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
34,589,1,3,,11111330,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
35,589,1,3,,11111331,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
36,590,1,3,,11111330,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
37,590,1,3,,11111331,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
38,591,1,4,,11111330,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
39,591,1,4,,11111331,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
40,592,1,6,,11111330,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
41,592,1,6,,11111331,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
42,593,1,4,,11111330,3696,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
43,593,1,4,,11111331,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
44,594,1,4,,11111330,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
45,594,1,4,,11111331,3696,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
46,595,1,3,,11111330,3696,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
47,595,1,3,,11111331,3696,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
48,596,1,2,,11111330,3696,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
49,596,1,2,,11111331,3696,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
50,597,1,3,,11111330,3696,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
51,597,1,3,,11111331,3696,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
52,603,1,2,,11111330,3696,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
53,603,1,2,,11111331,3696,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
54,605,1,2,,11111330,3696,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
55,605,1,2,,11111331,3696,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
56,607,1,3,,11111330,3696,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
57,607,1,3,,11111331,3696,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
58,662,1,1,,11111330,3696,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
59,662,1,1,,11111331,3696,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
60,875,1,2,,11111330,3696,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
61,875,1,2,,11111331,3696,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
62,879,1,2,,11111330,3696,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
63,879,1,2,,11111330,3696,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
64,880,2,1,,11111331,3696,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
65,880,2,1,,11111331,3696,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
66,880,2,1,,26751600,3696,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
67,880,2,1,,26751600,3696,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
68,881,2,2,,11111330,3696,Inactive,317373425.0,247.0,7.9433,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
69,881,2,2,,11111331,3696,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
70,883,1,3,,11111330,3696,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
71,883,1,3,,11111331,3696,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
72,884,1,2,,11111330,3696,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
73,884,1,2,,11111331,3696,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
74,885,1,2,,11111330,3696,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
75,885,1,2,,11111331,3696,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
76,886,1,2,,11111330,3696,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
77,886,1,2,,11111330,3696,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
78,886,1,2,,11111331,3696,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
79,886,1,2,,11111331,3696,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
80,887,1,2,,11111330,3696,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
81,887,1,2,,11111331,3696,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
82,889,1,3,,11111330,3696,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
83,889,1,3,,11111331,3696,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
84,891,1,2,,11111330,3696,Active,40805836.0,1565.0,25.1189,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
85,891,1,2,,11111331,3696,Active,40805836.0,1565.0,6.3096,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
86,892,1,2,,11111330,3696,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
87,892,1,2,,11111331,3696,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
88,893,1,2,,11111330,3696,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
89,893,1,2,,11111330,3696,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
90,893,1,2,,11111331,3696,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
91,893,1,2,,11111331,3696,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
92,894,2,1,,11111331,3696,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
93,895,1,2,,11111330,3696,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
94,899,1,2,,11111330,3696,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
95,899,1,2,,11111331,3696,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
96,900,1,3,,11111330,3696,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
97,900,1,3,,11111331,3696,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
98,901,1,2,,11111330,3696,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
99,901,1,2,,11111331,3696,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
100,902,1,2,,11111330,3696,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
101,902,1,2,,11111331,3696,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
102,912,1,2,,11111330,3696,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
103,912,1,2,,11111331,3696,Inconclusive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
104,914,1,3,,11111330,3696,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
105,914,1,3,,11111331,3696,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
106,915,1,3,,11111330,3696,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
107,915,1,3,,11111331,3696,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
108,917,1,3,,11111330,3696,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
109,918,1,3,,11111330,3696,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
110,923,1,2,,11111330,3696,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
111,923,1,2,,11111331,3696,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
112,924,1,2,,11111330,3696,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
113,924,1,2,,11111331,3696,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
114,925,1,2,,11111330,3696,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
115,925,1,2,,11111331,3696,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
116,926,1,2,,11111330,3696,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
117,926,1,2,,11111331,3696,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
118,927,1,3,,11111330,3696,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
119,927,1,3,,11111331,3696,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
120,928,1,2,,11111330,3696,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
121,938,1,2,,11111330,3696,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
122,938,1,2,,11111331,3696,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
123,943,1,2,,11111330,3696,Active,18249941.0,25229.0,0.3548,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
124,944,1,2,,11111330,3696,Active,18249941.0,25229.0,1.0,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
125,945,1,4,,11111330,3696,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
126,954,1,2,,11111330,3696,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
127,957,1,2,,11111330,3696,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
128,958,1,2,,11111330,3696,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
129,959,1,4,,11111330,3696,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
130,992,1,3,,11111330,3696,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
131,995,1,2,,11111330,3696,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
132,995,1,2,,11111331,3696,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
133,997,1,2,,11111330,3696,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
134,998,1,2,,11111330,3696,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
135,1030,2,1,,11111331,3696,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
136,1030,2,1,,26751600,3696,Inconclusive,30582681.0,216.0,5.6234,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
137,1332,1,1,,49698865,3696,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
138,1379,1,2,,11111331,3696,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
139,1452,1,1,,11111330,3696,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
140,1452,1,1,,11111331,3696,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
141,1454,1,1,,11111331,3696,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
142,1457,1,1,,11111331,3696,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
143,1457,1,1,,26751600,3696,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
144,1458,1,1,,11111331,3696,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
145,1458,1,1,,26751600,3696,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
146,1460,1,3,,26751600,3696,Inconclusive,92096784.0,4137.0,0.5623,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
147,1463,1,1,,26751600,3696,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
148,1467,1,3,,11111331,3696,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
149,1468,1,1,,26751600,3696,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
150,1469,1,1,,11111331,3696,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
151,1469,1,1,,26751600,3696,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
152,1471,2,1,,11111330,3696,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
153,1471,2,1,,11111331,3696,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
154,1471,2,1,,26751600,3696,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
155,1476,2,1,,11111331,3696,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
156,1477,1,1,,11111331,3696,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
157,1477,1,1,,26751600,3696,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
158,1478,2,1,,11111331,3696,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
159,1479,1,2,,11111331,3696,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
160,1479,1,2,,26751600,3696,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
161,1487,1,1,,11111331,3696,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
162,1487,1,1,,26751600,3696,Inconclusive,27436948.0,4000.0,0.7943,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
163,1490,2,1,,11111331,3696,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
164,1490,2,1,,26751600,3696,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
165,1519,1,3,,11111331,3696,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
166,1688,1,1,,26751600,3696,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
167,1766,1,1,,11111331,3696,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
168,1766,1,1,,11111331,3696,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
169,1766,1,1,,26751600,3696,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
170,1766,1,1,,26751600,3696,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
171,1768,1,1,,11111331,3696,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
172,1768,1,1,,11111331,3696,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
173,1768,1,1,,26751600,3696,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
174,1768,1,1,,26751600,3696,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
175,1851,1,2,,11111330,3696,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
176,1851,1,2,,11111331,3696,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
177,1851,1,2,1.0,11111330,3696,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
178,1851,1,2,1.0,11111331,3696,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
179,1851,1,2,2.0,11111330,3696,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
180,1851,1,2,2.0,11111331,3696,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
181,1851,1,2,3.0,11111330,3696,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
182,1851,1,2,3.0,11111331,3696,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
183,1851,1,2,4.0,11111330,3696,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
184,1851,1,2,4.0,11111331,3696,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
185,1851,1,2,5.0,11111330,3696,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
186,1851,1,2,5.0,11111331,3696,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
187,1865,1,1,,11111331,3696,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
188,1865,1,1,,26751600,3696,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
189,1948,1,1,,11111331,3696,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
190,2061,1,2,,85209458,3696,Active,,,,,Ligands of nucleotide-like (Class A) GPCRs,Other,,
191,2062,1,2,,85209458,3696,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
192,2101,1,1,,11111331,3696,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
193,2101,1,1,,26751600,3696,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
194,2107,1,1,,11111331,3696,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
195,2107,1,1,,26751600,3696,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
196,2112,1,1,,11111331,3696,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
197,2112,1,1,,26751600,3696,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
198,2147,1,1,,11111331,3696,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
199,2240,1,1,,85789342,3696,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
200,2241,1,1,,85789342,3696,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
201,2275,1,1,,85789342,3696,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
202,2313,1,1,,85789342,3696,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
203,2322,1,1,,85789342,3696,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
204,2330,1,1,,85789342,3696,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
205,2451,1,2,,11111331,3696,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
206,2472,1,2,,11111331,3696,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
207,2517,2,1,,11111331,3696,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
208,2517,2,1,,26751600,3696,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
209,2528,1,2,,11111331,3696,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
210,2528,1,2,,26751600,3696,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
211,2546,1,1,,11111331,3696,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
212,2546,1,1,,26751600,3696,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
213,2549,1,1,,11111331,3696,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
214,2549,1,1,,26751600,3696,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
215,2551,1,1,,11111331,3696,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
216,2551,1,1,,26751600,3696,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
217,2660,1,1,,90341377,3696,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
218,2666,1,1,,90341377,3696,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
219,2667,1,1,,90341377,3696,Inconclusive,4826730.0,2475.0,5.2119,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
220,2668,1,1,,90341377,3696,Inconclusive,4826730.0,2475.0,14.6892,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
221,5241,7,2,,103164240,3696,Active,,,0.023,Ki,Binding affinity towards 5-hydroxytryptamine 2 receptor,Confirmatory,3039136.0,
222,5355,7,2,,103164240,3696,Active,,,0.094,Ki,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Confirmatory,15081025.0,
223,5444,7,1,,103164240,3696,Active,,,0.16,Ki,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,Confirmatory,11266163.0,
224,5679,7,1,,103164240,3696,Active,,,0.16,Ki,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Confirmatory,11266163.0,
225,5945,7,2,,103164240,3696,Active,,,0.16,Ki,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Confirmatory,15081025.0,
226,6418,9,5,,103164240,3696,Active,112808.0,29595.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
227,6418,9,5,,103164240,3696,Active,112812.0,24473.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
228,6418,9,5,,103164240,3696,Active,112815.0,25075.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
229,6418,9,5,,103164240,3696,Active,112817.0,25187.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
230,6418,9,5,,103164240,3696,Active,112820.0,25323.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
231,6418,9,5,,103164240,3696,Active,398968.0,60448.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
232,6418,9,5,,103164240,3696,Active,398970.0,29581.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
233,6418,9,5,,103164240,3696,Active,461440.0,65032.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
234,6418,9,5,,103164240,3696,Active,543729.0,25689.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
235,6418,9,5,,103164240,3696,Active,543730.0,79247.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
236,6418,9,5,,103164240,3696,Active,1168221.0,64354.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
237,6418,9,5,,103164240,3696,Active,1168223.0,79246.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
238,6418,9,5,,103164240,3696,Active,2494928.0,25324.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
239,6418,9,5,,103164240,3696,Active,81868595.0,58963.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
240,7783,3,4,,103164240,3696,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
241,8002,5,2,,103164240,3696,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
242,15708,6,1,,103164240,3696,Unspecified,,,,,Plasma clearance for the compound was determined.,Other,10447960.0,
243,16331,3,4,,103164240,3696,Unspecified,,,,,Delta logPoct-cyc,Other,2894467.0,
244,19006,4,3,,103164240,3696,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
245,19257,4,3,,103164240,3696,Unspecified,,,,,Logarithm of partition coefficient of the neutral form of compound given for chloroform/water solvent system,Other,2894467.0,
246,19260,3,3,,103164240,3696,Unspecified,,,,,Logarithm of partition coefficient of the neutral form of compound given for octanol/water solvent system,Other,2894467.0,
247,19262,5,1,,103164240,3696,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
248,19419,3,4,,103164240,3696,Unspecified,,,,,Partition coefficient (logD7.4),Other,9544199.0,
249,19424,3,4,,103164240,3696,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
250,20050,3,3,,103164240,3696,Unspecified,,,,,Human absorption A (%),Other,9544199.0,
251,22345,3,3,,103164240,3696,Unspecified,,,,,Therapeutic plasma levels for the compound was evaluated.,Other,10447960.0,
252,22432,5,2,,103164240,3696,Unspecified,,,,,Volume of distribution in the plasma fluid was determined,Other,10447960.0,
253,22538,3,3,,103164240,3696,Unspecified,,,,,Half life period is estimated,Other,10447960.0,
254,23708,3,3,,103164240,3696,Unspecified,,,,,Partition coefficient (logP),Other,10447960.0,
255,23960,3,3,,103164240,3696,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
256,23962,4,3,,103164240,3696,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
257,23968,4,3,,103164240,3696,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
258,23970,4,3,,103164240,3696,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
259,23972,4,3,,103164240,3696,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
260,23973,4,3,,103164240,3696,Unspecified,,,,,"Partition coefficient (logD, measured by HPLC, log k')",Other,6167716.0,
261,23975,4,3,,103164240,3696,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
262,23976,4,3,,103164240,3696,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
263,24179,3,4,,103164240,3696,Unspecified,,,,,"logBB, log(C brain/C blood)",Other,8941388.0,
264,25866,3,3,,103164240,3696,Unspecified,,,,,Protonation constant of the compound.,Other,10447960.0,
265,26296,4,4,,103164240,3696,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
266,26300,3,5,,103164240,3696,Unspecified,,,,,log P values determined at PH 7.4,Other,10447960.0,
267,26310,4,4,,103164240,3696,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
268,26362,4,3,,103164240,3696,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
269,26515,3,4,,103164240,3696,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
270,26538,3,3,,103164240,3696,Unspecified,,,,,log K was measured potentiometrically in Brij35 medium,Other,10447960.0,
271,27167,3,4,,103164240,3696,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
272,27361,6,2,,103164240,3696,Unspecified,,,,,Dose of compound required in mg/kg to induce lethality in 50% of mice after 14 days,Other,2016710.0,
273,28233,3,3,,103164240,3696,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
274,28234,3,4,,103164240,3696,Unspecified,,,,,% absorbed in human GI-tract,Other,11300874.0,
275,28235,3,3,,103164240,3696,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
276,28236,3,3,,103164240,3696,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
277,28679,3,4,,103164240,3696,Unspecified,,,,,Partition coefficient (logD6.8),Other,11300874.0,
278,28681,3,4,,103164240,3696,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
279,28921,3,3,,103164240,3696,Unspecified,,,,,Partition coefficient (logP) (hexadecane),Other,11300874.0,
280,28923,3,4,,103164240,3696,Unspecified,,,,,Effective permeability measured with Caco-2 cells,Other,11300874.0,
281,28924,3,3,,103164240,3696,Unspecified,,,,,Effective permeability (Pe) across a hexadecane membrane (pH 6.8),Other,11300874.0,
282,28925,3,3,,103164240,3696,Unspecified,,,,,Highest effective permeability across hexadecane membrane (pH 4-8),Other,11300874.0,
283,28926,3,3,,103164240,3696,Unspecified,,,,,Effective permeability corrected for ionization,Other,11300874.0,
284,28928,3,3,,103164240,3696,Unspecified,,,,,Intrinsic permeability of the compound,Other,11300874.0,
285,29337,3,3,,103164240,3696,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
286,29359,3,3,,103164240,3696,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
287,29423,3,4,,103164240,3696,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
288,29812,3,3,,103164240,3696,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
289,29925,5,2,,103164240,3696,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
290,34292,8,2,,103164240,3696,Active,,,0.16,Ki,Compound was tested for its binding affinity towards brain (Hippocampus) Adenylate cyclase,Confirmatory,10447960.0,
291,34293,8,2,,103164240,3696,Active,,,0.16,Ki,Compound was tested for its binding affinity towards brain (neocortex) Adenylate cyclase,Confirmatory,10447960.0,
292,35284,7,3,,103164240,3696,Active,,,0.046,Ki,In vitro binding affinity at Alpha-1 adrenergic receptor by radioligand binding assay using [3H]prazosin,Confirmatory,,
293,36851,7,1,,103164240,3696,Active,,,0.16,IC50,Concentration of compound for 50% displacement of [3H]WB-4101 from Alpha-1 adrenergic receptor of rat brain,Confirmatory,6249933.0,
294,37375,7,2,,103164240,3696,Active,,,0.255,Ki,In vitro binding affinity at Alpha-2 adrenergic receptor in rat cortex by radioligand binding assay using [3H]rauwolscine,Confirmatory,,
295,48900,3,3,,103164240,3696,Unspecified,,,,,Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 1 mg/Kg,Other,11677127.0,
296,48901,3,3,,103164240,3696,Unspecified,,,,,Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 2 mg/Kg,Other,11677127.0,
297,48902,3,3,,103164240,3696,Unspecified,,,,,Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 3 mg/Kg,Other,11677127.0,
298,51930,6,6,,103164240,3696,Active,7531135.0,3757.0,3.4,IC50,K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1,Confirmatory,12190308.0,
299,60003,6,2,,103164240,3696,Unspecified,,,,,Inhibition of the response to phenethylamine was measured,Other,6747994.0,
300,60027,6,2,,103164240,3696,Unspecified,,,,,Potentiation of the response to norepinephrine was measured,Other,6747994.0,
301,61054,7,1,,103164240,3696,Active,,,0.726,Ki,Binding affinity to Dopamine receptor D2 using [3H]spiperone as radioligand in stably transfected NIH3T3 cells,Confirmatory,11266163.0,
302,62860,7,1,,103164240,3696,Active,,,0.645,IC50,Concentration of compound for 50% displacement of [3H]spiperone from Dopamine receptor in rat brain,Confirmatory,6249933.0,
303,63979,7,2,,103164240,3696,Active,,,0.726,Ki,Binding affinity towards dopamine receptor D2 using [3H]spiperone as radioligand,Confirmatory,15081025.0,
304,64630,4,7,,103164240,3696,Unspecified,,,,,Binding affinity towards dopamine receptor D2 at 1.0 uM concentration,Other,3039136.0,
305,78164,8,2,,103164240,3696,Unspecified,,,,,Concentration required to reducing the histamine induced contraction by 50% was measured,Other,7205881.0,
306,87513,8,2,,103164240,3696,Active,,,5.9999999999999995e-05,IC50,Compound tested for its inhibitory activity against Histamine H1 receptor,Confirmatory,10447960.0,
307,87880,7,6,,103164240,3696,Active,1346291.0,100729734.0,1.9,IC50,Inhibitory activity against brain adenylate cyclase Histamine H2 receptor,Confirmatory,10447960.0,
308,90053,8,2,,103164240,3696,Active,,,0.03,IC50,Binding affinity towards histamine receptor by inhibiting specific binding of [3H]-mepyramine (3 nM) in vitro to membranes of rat brain without cerebellum,Confirmatory,6747997.0,
309,91481,4,7,,103164240,3696,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
310,91721,11,1,,103164240,3696,Active,,,0.0017,IC50,Inhibition of binding of [3H]imipramine to imipramine receptor in rat brain,Confirmatory,1976813.0,
311,91833,4,3,,103164240,3696,Active,,,0.012,Ki,Binding affinity against imipramine receptor was determined in homogenized rat cortex tissue using [3H]-imipramine as radioligand,Confirmatory,3039133.0,
312,103232,4,4,,103164240,3696,Unspecified,,,,,Anti MDR activity was expressed as MDR ratio or MDR fold reversal in doxorubicin resistant human breast carcinoma tumor cell line MCF-7/DOX,Other,9599232.0,
313,107473,3,4,,103164240,3696,Unspecified,,,,,Compound was tested for total number of falls in 100 seconds after intraperitoneal administration of 37.5 mg/Kg in mice by rotarod test,Other,1335075.0,
314,110071,7,2,,103164240,3696,Unspecified,,,,,Antagonism of tetrabenazine (TBZ)-induced depression measured in mice by motor activity,Other,3039136.0,
315,110188,7,2,,103164240,3696,Unspecified,,,,,Antagonism of tetrabenazine (TBZ)-induced depression in mice measured for ptosis,Other,3039136.0,
316,111827,3,3,,103164240,3696,Unspecified,,,,,"Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 10 mg/kg",Other,6716406.0,
317,111833,4,3,,103164240,3696,Unspecified,,,,,"Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 20 mg/kg",Other,6716406.0,
318,111839,3,3,,103164240,3696,Unspecified,,,,,"Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 40.0 mg/kg",Other,6716406.0,
319,111841,3,3,,103164240,3696,Unspecified,,,,,"Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 5 mg/kg",Other,6716406.0,
320,112136,6,2,,103164240,3696,Unspecified,,,,,"Effective dose required to potentiate yohimbine hydrochloride induced lethality in mice, administered intraperitoneally",Other,4067998.0,
321,112145,6,2,,103164240,3696,Unspecified,,,,,"Effective dose required to prevent reserpine ptosis in mice, administered (po)orally",Other,4067998.0,
322,112146,6,2,,103164240,3696,Unspecified,,,,,"Effective dose required to prevent reserpine ptosis in mice, administered intraperitoneally",Other,4067998.0,
323,112169,6,2,,103164240,3696,Unspecified,,,,,Effective dose to reverse tetrabenazine ptosis in mouse when administered po,Other,6109026.0,
324,112173,6,2,,103164240,3696,Unspecified,,,,,Effective dose was evaluated for its antagonism to reserpine induced hypothermia in mice by intraperitoneal administration,Other,4045918.0,
325,112365,6,2,,103164240,3696,Unspecified,,,,,"The compound was tested for antidepressant activity by its ability to reverse tetrabenazine induced ptosis in mice, perorally",Other,7189216.0,
326,112381,6,2,,103164240,3696,Unspecified,,,,,The effect on 24-hour mortality in mice following oral administration,Other,7265119.0,
327,112383,6,2,,103164240,3696,Unspecified,,,,,The effect on ataxia in mice following oral administration,Other,7265119.0,
328,112385,6,2,,103164240,3696,Unspecified,,,,,The effect on electroshock protection in mice following oral administration,Other,7265119.0,
329,112387,6,2,,103164240,3696,Unspecified,,,,,The effect on excitement was measured in mice following oral administration,Other,7265119.0,
330,112388,6,2,,103164240,3696,Unspecified,,,,,Effect on pupil dilation was measured in mice upon oral administration,Other,7265119.0,
331,112481,6,2,,103164240,3696,Unspecified,,,,,Compound was tested for antidepressant activity against reserpine induced ptosis in mice after intraperitoneal administration.; value ranges from 2.2-2.4,Other,2563772.0,
332,112624,6,2,,103164240,3696,Unspecified,,,,,Compound was tested for antidepressant activity by determining the decreased exploratory activity in mice upon oral administration,Other,7265119.0,
333,112642,6,2,,103164240,3696,Unspecified,,,,,Antidepressant activity by determining the reversal of tetrabenazine-induced ptosis upon oral administration,Other,7265119.0,
334,112984,6,2,,103164240,3696,Unspecified,,,,,"Compound was tested for the inhibition of tetrabenazine-induced sedation in mice, after peroral administration",Other,8558500.0,
335,112987,6,2,,103164240,3696,Unspecified,,,,,Compound was tested for the neuroleptic activity as measured by it's antagonism of d-amphetamine induced lethality in grouped mice(GAL) when administered perorally,Other,6110781.0,
336,113292,6,2,,103164240,3696,Unspecified,,,,,Dose of compound required to reduce apomorphine-induced hypothermia by 50% in mice by hypothermia (Apo 16)test,Other,2016710.0,
337,113415,3,3,,103164240,3696,Unspecified,,,,,Compound was tested for total number of explored holes in 5 minutes after intraperitoneal administration of 37.5 mg/Kg in mice,Other,1335075.0,
338,113642,7,2,,103164240,3696,Unspecified,,,,,Effect on the antagonism of bicuculline-induced tonic-extensor convulsions (B),Other,6103959.0,
339,113644,7,2,,103164240,3696,Unspecified,,,,,Effect on the antagonism of nicotine-induced death (D),Other,6103959.0,
340,113646,7,2,,103164240,3696,Unspecified,,,,,Effect on the antagonism of nicotine-induced tonic-extensor convulsions (TE) in mice,Other,6103959.0,
341,113648,7,2,,103164240,3696,Unspecified,,,,,Effect on the antagonism of oxotremorine-induced hypothermia (OX),Other,6103959.0,
342,113650,6,2,,103164240,3696,Unspecified,,,,,Effect on the antagonism of pentylenetetrazole-induced clonic convulsions (P),Other,6103959.0,
343,113652,7,2,,103164240,3696,Unspecified,,,,,Effect of test compound on the potentiation of apomorphine-induced gnawing (AG) in aggregated mice,Other,6103959.0,
344,113655,7,2,,103164240,3696,Unspecified,,,,,Effect on the potentiation of gamma-butyrolactone-induced sleep (gamma-B),Other,6103959.0,
345,113656,7,2,,103164240,3696,Unspecified,,,,,Effect on the potentiation of yohimbine-induced toxicity (Y) in aggregated mice,Other,6103959.0,
346,113658,7,2,,103164240,3696,Unspecified,,,,,Effect on the prolongation of hypoxic survival time (HS),Other,6103959.0,
347,113875,5,2,,103164240,3696,Inactive,,,,,Intraperitoneal dose required for antagonism of d-amphetamine lethality in grouped mice (GAL).; inact means compound is inactive at 20 mg/kg dose.,Other,6103960.0,
348,114043,6,2,,103164240,3696,Unspecified,,,,,"Muscle relaxant effect was measured as ED50 which is the dose that causes muscle relaxation in 50% of the mice, po",Other,7205881.0,
349,114156,6,2,,103164240,3696,Unspecified,,,,,Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice,Other,3373495.0,
350,114157,6,2,,103164240,3696,Unspecified,,,,,Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice,Other,3373495.0,
351,114237,6,2,,103164240,3696,Unspecified,,,,,Serotonergic activity was determined by measuring the potentiation of 5-hydroxytryptophan in mice upon ip administration,Other,2563772.0,
352,114327,6,2,,103164240,3696,Unspecified,,,,,"Antiphysostigmine effect was measured as ED50,po",Other,7205881.0,
353,114386,7,2,,103164240,3696,Unspecified,,,,,Analgesic activity for the inhibition of phenylquinone induced writhing (PQW) after subcutaneous administration to mice,Other,6103962.0,
354,114392,6,2,,103164240,3696,Unspecified,,,,,Tested for antagonism of bicuculline-induced tonic-extensor convulsions (B) in mice,Other,6103958.0,
355,114393,6,2,,103164240,3696,Unspecified,,,,,Tested for antagonism of nicotine-induced death (D) in mice,Other,6103958.0,
356,114394,6,2,,103164240,3696,Unspecified,,,,,Tested for antagonism of nicotine-induced tonic extensor convulsions (TE) in mice,Other,6103958.0,
357,114395,6,2,,103164240,3696,Unspecified,,,,,Tested for antagonism of oxotremorine hypothermia (OX) in mice,Other,6103958.0,
358,114396,6,2,,103164240,3696,Unspecified,,,,,Tested for antagonism of pentylenetetrazole-induced clonic convulsions (P) in mice,Other,6103958.0,
359,114407,6,2,,103164240,3696,Unspecified,,,,,Anticonvulsant activity to prevent pentamethylenetetrazole (MTZ) induced lethality in mice after oral administration,Other,6103962.0,
360,114412,6,2,,103164240,3696,Unspecified,,,,,Antidepressant activity to prevent tetrabenazine induced ptosis (TBZ) in mice after intraperitoneal administration,Other,6103962.0,
361,114415,6,2,,103164240,3696,Unspecified,,,,,Antipsychotic activity to prevent amphetamine induced lethality in mice after oral administration,Other,6103962.0,
362,114488,6,2,,103164240,3696,Unspecified,,,,,Inhibition of reserpine (5 mg/kg i.p.) induced hypothermia in mice 2 hr after i.p. administration.,Other,6842518.0,
363,114489,6,2,,103164240,3696,Unspecified,,,,,Inhibition of reserpine (5 mg/kg i.p.) induced hypothermia in mice 4 hr after i.p. administration.,Other,6842518.0,
364,114561,6,2,,103164240,3696,Unspecified,,,,,Tested for potentiation of gamma-butyrolactone induced sleep (gamma-B) in mice,Other,6103958.0,
365,114562,6,2,,103164240,3696,Unspecified,,,,,Tested for potentiation of yohimbine toxicity in aggregated mice(Y),Other,6103958.0,
366,114563,6,2,,103164240,3696,Unspecified,,,,,Prolongation of hypoxic survival time (HS) in mice,Other,6103958.0,
367,114565,6,2,,103164240,3696,Unspecified,,,,,Tested for stereotyped gnawing and licking behavior of mice pretreated with apomorphine (AG),Other,6103958.0,
368,114738,6,2,,103164240,3696,Unspecified,,,,,Delay in response to noxious heat stimuli in mice by tail flick method after subcutaneous administration,Other,6103962.0,
369,114920,3,3,,103164240,3696,Unspecified,,,,,Compound was evaluated after 24 hr for physostigmine induced lethality upon oral administration 60 min before intraperitoneal injection of physostigmine (0.9 mg/kg) in mice at 25 mg/kg,Other,2016710.0,
370,114922,3,3,,103164240,3696,Unspecified,,,,,Compound was evaluated after 24 hr for physostigmine induced lethality upon oral administration 60 min before intraperitoneal injection of physostigmine (0.9 mg/kg) in mice at 50 mg/kg,Other,2016710.0,
371,115594,4,3,,103164240,3696,Unspecified,,,,,Ability to modify turning behavior of mice after intraperitoneal administration,Other,2563772.0,
372,115619,3,3,,103164240,3696,Unspecified,,,,,Minimum effective dose causing antagonism of tetrabenazine induced depression in mice was determined when administered perorally,Other,6110781.0,
373,115754,3,3,,103164240,3696,Unspecified,,,,,Minimum effective dose was measured orally by antagonism of tetrabenazine-induced depression in mice(po),Other,6103960.0,
374,116717,6,2,,103164240,3696,Unspecified,,,,,Acute cytotoxicity was evaluated as LD50 in mice (ip),Other,3373495.0,
375,116867,3,3,,103164240,3696,Unspecified,,,,,Compound at an intraperitoneal dose of 10 mg/Kg was tested for the inhibition of abdominal constriction in mice,Other,1335075.0,
376,117217,6,2,,103164240,3696,Unspecified,,,,,Lethal dose was evaluated against reserpine induced hypothermia in mice by intraperitoneal administration,Other,4045918.0,
377,117244,6,2,,103164240,3696,Unspecified,,,,,"Toxicity was measured as LD50,po",Other,7205881.0,
378,118210,3,3,,103164240,3696,Unspecified,,,,,Ability to prevent the reserpine induced hypothermia in mice relative to amitriptyline,Other,7205881.0,
379,118790,3,3,,103164240,3696,Unspecified,,,,,Retention for passive avoidance learning in mice at dose 20 mg/kg,Other,7265121.0,
380,118792,3,3,,103164240,3696,Unspecified,,,,,Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 40 mg/kg,Other,7265121.0,
381,118793,3,3,,103164240,3696,Unspecified,,,,,Retention for passive avoidance learning in mice at dose 5 mg/kg,Other,7265121.0,
382,118797,3,3,,103164240,3696,Unspecified,,,,,Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 10 mg/kg,Other,7265121.0,
383,118917,5,2,,103164240,3696,Unspecified,,,,,Compound was tested for lethality in mice at a dose 80 mg/kg intraperitoneally; L denotes lethal at this dose,Other,7265121.0,
384,119032,3,3,,103164240,3696,Unspecified,,,,,Percentage protection against NMDA-induced lethality in mice by the compound at 20 mg/Kg administered ip 60 mins before iv administration of NMDA in the lethal dose of 90 mg/Kg.,Other,7636857.0,
385,119033,3,3,,103164240,3696,Unspecified,,,,,Percentage protection against NMDA-induced lethality in mice by the compound at 40 mg/Kg administered ip 60 mins before iv administration of NMDA in the lethal dose of 90 mg/Kg.,Other,7636857.0,
386,119097,3,3,,103164240,3696,Unspecified,,,,,Rotation number in mice was determined at 12 minutes after a dose of 10 mg/Kg,Other,1335075.0,
387,119216,3,3,,103164240,3696,Unspecified,,,,,Rotation number in mice was determined at 15 minutes after a dose of 10 mg/Kg,Other,1335075.0,
388,119219,3,3,,103164240,3696,Unspecified,,,,,Rotation number in mice was determined at 9 minutes after a dose of 10 mg/Kg,Other,1335075.0,
389,119457,3,4,,103164240,3696,Unspecified,,,,,"Dose required to reduce reserpine induced hypothermia was measured after sc administration of reserpine at 2.5 mg/kg, 18 hr before the rectal-temperature recording in mice",Other,2016710.0,
390,119877,3,3,,103164240,3696,Unspecified,,,,,Compound was tested for total number of movements in 5 minutes after intraperitoneal administration of 37.5 mg/Kg in mice,Other,1335075.0,
391,122478,3,3,,103164240,3696,Unspecified,,,,,Compound was tested for myorelaxant action (time in seconds on the horizontal wire with forelegs) after intraperitoneal administration of 37.5 mg/Kg in mice by traction test,Other,1335075.0,
392,123344,3,3,,103164240,3696,Unspecified,,,,,Percentage of total immobility time after an intraperitoneal dose of 1.5 (mg\\kg) in porsolt's test,Other,12408724.0,
393,123347,3,3,,103164240,3696,Unspecified,,,,,Percentage of total immobility time after an intraperitoneal dose of 30 (mg\\kg) in porsolt's test,Other,12408724.0,
394,123350,3,3,,103164240,3696,Unspecified,,,,,Percentage of total immobility time after an intraperitoneal dose of 7.5 (mg\\kg) in porsolt's test,Other,12408724.0,
395,124991,3,3,,103164240,3696,Unspecified,,,,,Writhing number was determined against clonidine induced analgesia by the compound at an intraperitoneal dose of 10 mg/Kg in mice,Other,1335075.0,
396,125386,6,3,,103164240,3696,Unspecified,,,,,"Effective dose (p.o.) required to inhibit monoamine oxidase, in vivo",Other,6747994.0,
397,125388,6,1,,103164240,3696,Unspecified,,,,,In vitro inhibitory concentration against monoamine oxidase with 5-HT as substrate,Other,6747994.0,
398,127789,6,2,,103164240,3696,Active,,,1.3,EC50,In vitro activity for the ability to inhibit the uptake of Norepinephrine into mouse cortical slices.,Confirmatory,4009610.0,
399,127795,6,2,,103164240,3696,Active,,,0.3,EC50,In vitro activity for the ability to inhibit the uptake of Serotonin into mouse cortical slices.,Confirmatory,4009610.0,
400,127858,6,2,,103164240,3696,Unspecified,,,,,Evaluated in vivo for reserpine hypothermia after oral administration in mouse. Minimum active dose was reported,Other,6716399.0,
401,128144,7,2,,103164240,3696,Unspecified,,,,,Ability to inhibit the uptake of Norepinephrine into mouse cortical slices 1 hour after intraperitoneal injection ex vivo,Other,4009610.0,
402,128147,7,2,,103164240,3696,Unspecified,,,,,Ability to inhibit the uptake of Serotonin into mouse cortical slices 1 hour after intraperitoneal injection ex vivo,Other,4009610.0,
403,128658,6,2,,103164240,3696,Unspecified,,,,,"Analgesic activity was determined for delay in response to noxious heat stimuli after subcutaneous administration in mice, in tail flick assay",Other,6128417.0,
404,128659,6,2,,103164240,3696,Unspecified,,,,,Analgesic activity was determined for inhibition of phenyl-p-quinone-induced writhing (PQW) after subcutaneous administration in mice,Other,6128417.0,
405,129176,6,2,,103164240,3696,Unspecified,,,,,Antidepressant activity measured by maximal electroshock seizure threshold (MEST) assay in TBZ treated mice after ip administration,Other,6747990.0,
406,129177,6,2,,103164240,3696,Unspecified,,,,,Antidepressant activity measured by maximal electroshock seizure threshold (MEST) assay in untreated mice after ip administration,Other,6747990.0,
407,129179,7,2,,103164240,3696,Unspecified,,,,,Antidepressant activity was determined to prevent tetrabenazine-induced ptosis(TBZ) after oral administration in mice,Other,6128417.0,
408,129450,6,2,,103164240,3696,Unspecified,,,,,"Anti-tetrabenazine (TBZ) activity, ability to prevent TBZ-induced ptosis in mice",Other,6471069.0,
409,129955,6,2,,103164240,3696,Unspecified,,,,,Antidepressant activity measured by effects on tetrabenzidine (TBZ) inhibited exploratory activity.,Other,6747990.0,
410,129961,6,2,,103164240,3696,Unspecified,,,,,Antidepressant activity measured by tetrabenazine (TBZ) induced ptosis in mice after intraperitoneal administration,Other,6747990.0,
411,130125,6,2,,103164240,3696,Unspecified,,,,,Compound was evaluated for maximal electroshock antagonism (MES) against mice,Other,6716399.0,
412,130699,7,3,,103164240,3696,Unspecified,,,,,In vivo inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices after intraperitoneal administration,Other,6458703.0,
413,130700,7,4,,103164240,3696,Unspecified,,,,,In vivo inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices after intraperitoneal administration,Other,6458703.0,
414,130716,6,2,,103164240,3696,Unspecified,,,,,In vivo inhibition of uptake of nor epinephrine in mouse heart; value ranges from 3.1-14.6,Other,4009590.0,
415,130904,6,2,,103164240,3696,Unspecified,,,,,Inhibition of radioactive NE [3H]norepinephrine uptake into mouse heart,Other,6716399.0,
416,131526,7,2,,103164240,3696,Unspecified,,,,,Effective dose against tetrabenazine induced ptosis in mice administered orally,Other,2861285.0,
417,131528,6,2,,103164240,3696,Unspecified,,,,,Effective dose against tetrabenazine induced ptosis in mice administered subcutaneously,Other,2861285.0,
418,131702,6,2,,103164240,3696,Unspecified,,,,,Effective dose (p.o.) required to reverse ptosis induced by tetrabenazine in mouse,Other,6747994.0,
419,131718,6,2,,103164240,3696,Unspecified,,,,,Effective dose against oxotremorine induced lacrimation,Other,6747994.0,
420,131719,6,2,,103164240,3696,Unspecified,,,,,Effective dose against oxotremorine induced tremor,Other,6747994.0,
421,131880,6,2,,103164240,3696,Unspecified,,,,,Effective dose required for inhibition of tetrabenazine-induced ptosis in mouse by peroral administration;Values ranges from: 1.8-9.3,Other,3039138.0,
422,131890,5,2,,103164240,3696,Inconclusive,,,,,Effective dose required to antagonise clonidine-induced antinociception(ACA) in mouse by peroral administration; NT is Not Tested,Other,3039138.0,
423,131997,3,3,,103164240,3696,Unspecified,,,,,Evaluated for antagonism of reserpine induced hypothermia,Other,6716399.0,
424,132107,6,2,,103164240,3696,Unspecified,,,,,In vivo effect on Tetrabenazine motor activity in mice following i.p. administration.,Other,2213832.0,
425,132108,6,2,,103164240,3696,Unspecified,,,,,In vivo effect on Tetrabenazine ptosis activity in mice following i.p. administration.,Other,2213832.0,
426,132117,7,2,,103164240,3696,Unspecified,,,,,Tested in vivo for head twitches antagonizing activity in mice,Other,2213832.0,
427,132403,6,2,,103164240,3696,Unspecified,,,,,"Electrical shock aggression was evaluated in mice, administered intraperitoneally",Other,4067998.0,
428,132665,6,3,,103164240,3696,Active,,,1.3,IC50,In vitro inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices,Confirmatory,6458703.0,
429,132666,6,4,,103164240,3696,Active,,,0.3,IC50,In vitro inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices,Confirmatory,6458703.0,
430,132963,3,3,,103164240,3696,Unspecified,,,,,Effect on tetrabenazine-induced suppression of locomotor activity in the mouse after peroral administration,Other,3968690.0,
431,133113,3,3,,103164240,3696,Unspecified,,,,,Prevention of reserpine-induced ptosis in the mouse after peroral administration,Other,3968690.0,
432,134215,7,2,,103164240,3696,Unspecified,,,10.0,Ki,Tested in vitro for dopamine(DA) neuronal uptake inhibition,Confirmatory,2213832.0,
433,134216,7,2,,103164240,3696,Active,,,0.012,Ki,Tested in vitro for norepinephrine (NE) neuronal uptake inhibition,Confirmatory,2213832.0,
434,134217,7,2,,103164240,3696,Active,,,0.042,Ki,Tested in vitro for serotonin(5-HT) neuronal uptake inhibition,Confirmatory,2213832.0,
435,134376,6,2,,103164240,3696,Unspecified,,,,,Acute toxicity was measured in mice after peroral administration (293-330),Other,2861285.0,
436,134408,6,2,,103164240,3696,Unspecified,,,,,Compound was evaluated for 50% lethal dose in mice; LD50 range 100-300 mg/kg,Other,6747990.0,
437,134420,6,2,,103164240,3696,Unspecified,,,,,"Lethal dose in mouse, in groups of ten",Other,6716399.0,
438,134601,6,2,,103164240,3696,Unspecified,,,,,Lethal dose in mouse i.p.,Other,4067998.0,
439,134602,6,2,,103164240,3696,Unspecified,,,,,Lethal dose in mouse p.o.,Other,4067998.0,
440,134634,3,3,,103164240,3696,Unspecified,,,,,Antagonism of reserpine-induced hypothermia in mice,Other,4009590.0,
441,134948,3,3,,103164240,3696,Active,,,,,Mouse behavior activity was determined; S-D=Stimulant-Depressant,Other,6716399.0,
442,135326,5,2,,103164240,3696,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
443,137278,3,3,,103164240,3696,Unspecified,,,,,Reserpine hypothermia antagonism in mouse administered perorally with 5 mg/kg of reserpine 2 hour prior to test compound administration,Other,6716399.0,
444,141547,7,1,,103164240,3696,Active,,,0.26899999999999996,IC50,Concentration of compound for 50% displacement of [3H]QNB from Muscarinic acetylcholine receptor in rat brain,Confirmatory,6249933.0,
445,142220,7,1,,103164240,3696,Active,,,0.065,Ki,Binding affinity against Muscarinic acetylcholine receptor was determined in homogenized rat cortex tissue using [3H]N-methylscopolamine as radioligand,Confirmatory,3039133.0,
446,142503,9,1,,103164240,3696,Active,,,0.3,IC50,Binding affinity towards muscarinic acetylcholine receptor by inhibiting specific binding of [3H]quinuclidinyl benzilate (0.8 nM) in vitro to membranes of rat brain without cerebellum,Confirmatory,6747997.0,
447,144767,9,5,,103164240,3696,Active,548372.0,24410.0,14.0,IC50,Inhibition of [3H]MK-801 binding to NMDA receptor of rat cerebral cortical synaptic membrane,Confirmatory,7636857.0,
448,144767,9,5,,103164240,3696,Active,548374.0,24411.0,14.0,IC50,Inhibition of [3H]MK-801 binding to NMDA receptor of rat cerebral cortical synaptic membrane,Confirmatory,7636857.0,
449,144767,9,5,,103164240,3696,Active,548379.0,24408.0,14.0,IC50,Inhibition of [3H]MK-801 binding to NMDA receptor of rat cerebral cortical synaptic membrane,Confirmatory,7636857.0,
450,144767,9,5,,103164240,3696,Active,3915771.0,24409.0,14.0,IC50,Inhibition of [3H]MK-801 binding to NMDA receptor of rat cerebral cortical synaptic membrane,Confirmatory,7636857.0,
451,144767,9,5,,103164240,3696,Active,18202594.0,24412.0,14.0,IC50,Inhibition of [3H]MK-801 binding to NMDA receptor of rat cerebral cortical synaptic membrane,Confirmatory,7636857.0,
452,144767,9,5,,103164240,3696,Active,51701630.0,170796.0,14.0,IC50,Inhibition of [3H]MK-801 binding to NMDA receptor of rat cerebral cortical synaptic membrane,Confirmatory,7636857.0,
453,144767,9,5,,103164240,3696,Active,51701631.0,191573.0,14.0,IC50,Inhibition of [3H]MK-801 binding to NMDA receptor of rat cerebral cortical synaptic membrane,Confirmatory,7636857.0,
454,145696,7,1,,103164240,3696,Active,,,0.016,Ki,Binding affinity to Norepinephrine transporter using [3H]-nisoxatine as radioligand in stably transfected NIH3T3 cells,Confirmatory,11266163.0,
455,145895,7,2,,103164240,3696,Active,,,0.016,Ki,Binding affinity towards Norepinephrine transporter using [3H]nisoxitine as radioligand,Confirmatory,15081025.0,
456,147591,8,2,,103164240,3696,Active,,,0.046,IC50,Compound was tested for its inhibitory activity against Noradrenaline receptor,Confirmatory,10447960.0,
457,161281,10,5,,103164240,3696,Active,7531135.0,3757.0,3.38844,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
458,161627,9,2,,103164240,3696,Active,,,10.0,EC50,Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells,Confirmatory,12904059.0,
459,172472,3,3,,103164240,3696,Unspecified,,,,,"Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 0.625 mg/kg in fasted rats",Other,7328600.0,
460,172473,3,3,,103164240,3696,Unspecified,,,,,"Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 1.25 mg/kg in fasted rats",Other,7328600.0,
461,172474,3,3,,103164240,3696,Unspecified,,,,,"Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 10 mg/kg in fasted rats",Other,7328600.0,
462,172608,3,3,,103164240,3696,Unspecified,,,,,"Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 2.5 mg/kg in fasted rats",Other,7328600.0,
463,172609,3,3,,103164240,3696,Unspecified,,,,,"Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 5 mg/kg in fasted rats",Other,7328600.0,
464,172611,3,3,,103164240,3696,Unspecified,,,,,"Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 0.625 mg/kg in fasted rats",Other,7328600.0,
465,172612,3,3,,103164240,3696,Unspecified,,,,,"Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 1.25 mg/kg in fasted rats",Other,7328600.0,
466,172613,3,3,,103164240,3696,Unspecified,,,,,"Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 10 mg/kg in fasted rats",Other,7328600.0,
467,172614,3,3,,103164240,3696,Unspecified,,,,,"Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 2.5 mg/kg in fasted rats",Other,7328600.0,
468,172615,3,3,,103164240,3696,Unspecified,,,,,"Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 5 mg/kg in fasted rats",Other,7328600.0,
469,173926,3,3,,103164240,3696,Unspecified,,,,,Potentiation of Methamphetamine effect for intracranial self stimulation(SS) in rats,Other,7328600.0,
470,176192,6,2,,103164240,3696,Unspecified,,,,,Effective dose to block muricidal behavior in rat when administered ip,Other,6109026.0,
471,176472,6,2,,103164240,3696,Unspecified,,,,,Potency to produce a significant inhibition of immobility in rat,Other,10229633.0,
472,178315,6,2,,103164240,3696,Unspecified,,,,,Antidepressant activity was determined for potentiation of head twitching induced by 5-hydroxytryptophan-(5-HTP) after intraperitoneal administration in pargyline-pretreated rats,Other,6128417.0,
473,178370,6,2,,103164240,3696,Unspecified,,,,,Effective dose (p.o.) required to reverse ptosis induced by tetrabenazine in rat,Other,6747994.0,
474,178876,6,2,,103164240,3696,Unspecified,,,,,"Compound was tested for the inhibition of tetrabenazine-induced sedation in rat, after peroral administration",Other,8558500.0,
475,179153,3,3,,103164240,3696,Unspecified,,,,,Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 20 mg/kg,Other,15115407.0,
476,179154,3,3,,103164240,3696,Unspecified,,,,,Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 30 mg/kg,Other,15115407.0,
477,179155,3,3,,103164240,3696,Unspecified,,,,,Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 40 mg/kg,Other,15115407.0,
478,179383,4,3,,103164240,3696,Active,,,0.16899999999999998,IC50,Concentration of compound to inhibit 50% of [3H]norepinephrine neurotransmitter uptake in rat brain,Confirmatory,6249933.0,
479,179384,4,3,,103164240,3696,Active,,,0.384,IC50,Concentration of compound to inhibit 50% of [3H]-5-HT neurotransmitter uptake in rat brain,Confirmatory,6249933.0,
480,179398,4,5,,103164240,3696,Active,,,0.105,IC50,Concentration required for its norepinephrine reuptake inhibitory activity in synaptosomal rat hyphalamic preparations,Confirmatory,,
481,179763,6,3,,103164240,3696,Active,,,0.24,IC50,In vitro inhibitory activity against [3H]5-HT uptake into crude synaptosomes from whole rat brain.,Confirmatory,3968690.0,
482,179927,7,6,,103164240,3696,Active,400629.0,25553.0,0.81,IC50,"Inhibition of 5-HT uptake in synaptosomal preparation from rat corpus striatum, using [3H]5-HT",Confirmatory,6492080.0,
483,179941,6,2,,103164240,3696,Active,,,0.027000000000000003,IC50,Inhibition of Norepinephrine uptake from rat diencephalon-midbrain,Confirmatory,2985785.0,
484,179960,6,4,,103164240,3696,Active,,,20.0,IC50,"Inhibition of dopamine uptake in synaptosomal preparation in rat corpus striatum, using [3H]dopamine",Confirmatory,6492080.0,
485,179973,6,4,,103164240,3696,Active,,,0.06,IC50,"Inhibition of norepinephrine uptake in synaptosomal preparation fro rat hypothalamus, using [3H]norepinephrine",Confirmatory,6492080.0,
486,179990,6,2,,103164240,3696,Unspecified,,,,,Tested in vivo for serotonin syndrome antagonizing activity in rat,Other,2213832.0,
487,180113,6,2,,103164240,3696,Active,,,5.3,IC50,Inhibition of the 5-HT [14C]5-HT uptake by rat brain slices In vitro,Confirmatory,6716399.0,
488,180114,6,2,,103164240,3696,Active,,,3.8,IC50,Inhibition of the NE [3H]Norepinephrine uptake by rat brain slices In vitro,Confirmatory,6716399.0,
489,180129,6,2,,103164240,3696,Active,,,16.0,IC50,Inhibition of uptake of 5-HT in rat brain slices,Confirmatory,4009590.0,
490,180130,6,2,,103164240,3696,Active,,,12.0,IC50,Inhibition of uptake of Dopamine in rat brain slices,Confirmatory,4009590.0,
491,180131,6,2,,103164240,3696,Active,,,4.6,IC50,Inhibition of uptake of nor epinephrine in rat brain slices,Confirmatory,4009590.0,
492,180132,6,5,,103164240,3696,Active,,,0.26,IC50,Inhibition of uptake of tritiated norepinephrine (NE) into rat brain synaptosomes,Confirmatory,1976813.0,
493,180133,6,5,,103164240,3696,Active,,,0.12,IC50,Inhibition of uptake of tritiated serotonin (5-HT) into rat brain synaptosomes,Confirmatory,1976813.0,
494,180151,6,3,,103164240,3696,Active,,,0.085,IC50,Inhibitory activity against uptake of [3H]norepinephrine into rat brain synaptosomes.,Confirmatory,2861285.0,
495,180366,6,2,,103164240,3696,Unspecified,,,,,The compound was tested for antidepressant activity by its ability to inhibit muricidal intraperitoneally,Other,7189216.0,
496,180468,6,3,,103164240,3696,Active,,,3.1,IC50,In vitro inhibitory activity against [3H]-5-HT uptake into crude synaptosomes from whole rat brain.,Confirmatory,3968690.0,
497,181621,3,3,,103164240,3696,Unspecified,,,,,Antimuricide effect was observed in the olfactory bulb removed rats; antimuricide effect at 30 mg/kg; + = 31 - 50%,Other,7205881.0,
498,181669,6,3,,103164240,3696,Active,,,5.0,IC50,In vitro inhibition of norepinephrine uptake in rat brain synaptosomes using [3H]NE,Confirmatory,6471069.0,
499,181670,6,3,,103164240,3696,Active,,,0.23,IC50,In vitro inhibition of 5-HT uptake in rat brain synaptosomes using [3H]- 5-hydroxytryptamine,Confirmatory,6471069.0,
500,183074,3,3,,103164240,3696,Unspecified,,,,,Inhibition of GABA uptake from rat diencephalon-midbrain at 100 uM concentration,Other,2985785.0,
501,183626,3,3,,103164240,3696,Unspecified,,,,,Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 20 mg/kg,Other,15115407.0,
502,183627,3,3,,103164240,3696,Unspecified,,,,,Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 30 mg/kg,Other,15115407.0,
503,183628,3,3,,103164240,3696,Unspecified,,,,,Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 40 mg/kg,Other,15115407.0,
504,184234,3,3,,103164240,3696,Unspecified,,,,,Maximum inhibition of immobility in the rat (Expressed as percentage of immobility observed in vehicle controls),Other,10229633.0,
505,184473,3,3,,103164240,3696,Unspecified,,,,,Reduction in motor activity in rats following p.o. administration.,Other,6110781.0,
506,184476,3,3,,103164240,3696,Unspecified,,,,,Estimated oral dose depressing motor activity by 50% in rats(po),Other,6103960.0,
507,184683,3,3,,103164240,3696,Unspecified,,,,,Minimal effective dose in an rat anti-immobility effect using behavioral despair test,Other,2374150.0,
508,185200,3,3,,103164240,3696,Unspecified,,,,,Time-related potentiation of methamphetamine-induced anorexia in rats at the lowest active dose.,Other,7328600.0,
509,193219,3,3,,103164240,3696,Unspecified,,,,,"Percentage decrease in immobility time, after acute administration (intraperitoneally) in rat dosed at 20 mg/kg",Other,11300875.0,
510,193220,3,3,,103164240,3696,Unspecified,,,,,"Percentage decrease in immobility time, after subchronic administration (intraperitoneally) in rat dosed at 20 mg/kg",Other,11300875.0,
511,195890,6,2,,103164240,3696,Unspecified,,,10.0,IC50,In vitro inhibition of dopamine (DA) uptake in synaptosomal preparation of rat brain,Confirmatory,8558500.0,
512,196022,6,2,,103164240,3696,Active,,,0.04,IC50,In vitro inhibition of norepinephrine (NE) uptake in synaptosomal preparation of rat brain,Confirmatory,8558500.0,
513,196023,6,2,,103164240,3696,Active,,,0.5,IC50,In vitro inhibition of serotonin uptake in synaptosomal preparation of rat brain,Confirmatory,8558500.0,
514,196028,6,3,,103164240,3696,Active,,,0.13,IC50,Inhibition of [3H]dopamine uptake into rat brain synaptosomes in vitro;Values ranges from: 0.09-0.18,Confirmatory,3039138.0,
515,196031,6,3,,103164240,3696,Active,,,0.03,IC50,Inhibition of [3H]norepinephrine uptake into rat brain synaptosomes in vitro;Values ranges from: 0.01-0.07,Confirmatory,3039138.0,
516,196036,6,3,,103164240,3696,Active,,,0.18,IC50,Inhibition of [3H]5-HT uptake into rat brain synaptosomes in vitro;Values ranges from: 0.14-0.22,Confirmatory,3039138.0,
517,196059,7,3,,103164240,3696,Unspecified,,,10.0,Ki,Inhibition of the uptake of tritiated dopamine (DA) in rat synaptosomes,Confirmatory,3039136.0,
518,196062,7,3,,103164240,3696,Active,,,0.012,Ki,Inhibition of uptake of tritiated norepinephrine (NE) in rat synaptosomes,Confirmatory,3039136.0,
519,196063,7,3,,103164240,3696,Active,,,0.0418,Ki,Inhibition the uptake of tritiated serotonin (5-HT) by the serotonin transporter SERT in rat synaptosomes,Confirmatory,3039136.0,
520,203916,3,10,,103164240,3696,Unspecified,112812.0,24473.0,,,Binding affinity towards serotonin S1 receptor at 1.0 uM,Other,3039136.0,
521,203916,3,10,,103164240,3696,Unspecified,112815.0,25075.0,,,Binding affinity towards serotonin S1 receptor at 1.0 uM,Other,3039136.0,
522,203916,3,10,,103164240,3696,Unspecified,112820.0,25323.0,,,Binding affinity towards serotonin S1 receptor at 1.0 uM,Other,3039136.0,
523,203916,3,10,,103164240,3696,Unspecified,398968.0,60448.0,,,Binding affinity towards serotonin S1 receptor at 1.0 uM,Other,3039136.0,
524,204217,7,2,,103164240,3696,Active,,,0.005,Ki,Binding affinity to Serotonin transporter using [3H]-paroxetine as radioligand in stably transfected NIH3T3 cells,Confirmatory,11266163.0,
525,204880,7,3,,103164240,3696,Active,,,0.005,Ki,Binding affinity towards Serotonin transporter using [3H]paroxetine as radioligand,Confirmatory,15081025.0,
526,205267,9,2,,103164240,3696,Active,,,3.6,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
527,205268,4,7,,103164240,3696,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
528,211846,6,3,,103164240,3696,Unspecified,,,,,Acute toxicity (p.o.) after 24 hr was determined in mouse,Other,6747994.0,
529,214939,7,3,,103164240,3696,Unspecified,,,310.0,Km,Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4),Confirmatory,12699380.0,
530,218673,7,2,,103164240,3696,Active,,,0.22,Ki,Binding affinity towards alpha-1 adrenergic receptor,Confirmatory,3039136.0,
531,218807,7,2,,103164240,3696,Active,,,4.9,Ki,Binding affinity towards alpha-2 adrenergic receptor,Confirmatory,3039136.0,
532,221731,7,2,,103164240,3696,Unspecified,,,,,"Ability to kill 50% of the animals after 24h, when administered perorally",Other,3806614.0,
533,222068,3,4,,103164240,3696,Inconclusive,,,,,Effect on the sleeping time of mice anesthetized with halothane (treated group);NT means not tested,Other,10649973.0,
534,222070,3,4,,103164240,3696,Inconclusive,,,,,Effect on the sleeping time of mice before halothane load (control group);NT means not tested,Other,10649973.0,
535,222711,4,3,,103164240,3696,Unspecified,,,,,Effect on recovery time for coma induced in mice by cerebral concussion (control group),Other,10649973.0,
536,222712,4,3,,103164240,3696,Unspecified,,,,,Effect on recovery time for coma induced in mice by cerebral concussion (treated group),Other,10649973.0,
537,222978,7,2,,103164240,3696,Unspecified,,,,,Antagonism of tetrabenazine-induced ptosis in mice was evaluated after oral administration,Other,3806614.0,
538,223123,7,2,,103164240,3696,Unspecified,,,,,Potentiation of 5-hydroxytryptophan-induced head twitch in mice after oral administration,Other,3806614.0,
539,223128,7,2,,103164240,3696,Unspecified,,,,,"Ability to kill 50% of the animals (administered orally), after sublethal dose of yohimbine (25 mg/Kg) when given subcutaneously.",Other,3806614.0,
540,224550,3,3,,103164240,3696,Unspecified,,,,,Percent increase of the diameter of the test pupil (% mydriasis) in comparison with that of the control pupil.,Other,3806614.0,
541,225158,3,3,,103164240,3696,Unspecified,,,,,Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 0 mg/kg po for repeated administration,Other,10649973.0,
542,225159,3,3,,103164240,3696,Unspecified,,,,,Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 0 mg/kg po for single administration,Other,10649973.0,
543,225161,3,3,,103164240,3696,Unspecified,,,,,Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 10 mg/kg po for repeated administration,Other,10649973.0,
544,225162,3,3,,103164240,3696,Unspecified,,,,,Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 10 mg/kg po for single administration,Other,10649973.0,
545,225164,3,3,,103164240,3696,Unspecified,,,,,Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 30 mg/kg po for repeated administration,Other,10649973.0,
546,225165,3,3,,103164240,3696,Unspecified,,,,,Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 30 mg/kg po for single administration,Other,10649973.0,
547,225960,3,3,,103164240,3696,Unspecified,,,,,Minimum effective dose required for inhibition of serotonin uptake was determined by PCA method in rat by peroral administration,Other,3039138.0,
548,229207,5,1,,103164240,3696,Inconclusive,,,,,Binding affinity for sigma receptors was evaluated by the inhibitory effect on [3H]DTG to rat whole brain membranes;NT means not tested.,Other,10649973.0,
549,235625,3,3,,103164240,3696,Unspecified,,,,,Therapeutic index administered intraperitoneally in mouse,Other,4067998.0,
550,235626,3,3,,103164240,3696,Unspecified,,,,,Therapeutic index administered perorally in mouse,Other,4067998.0,
551,235738,3,3,,103164240,3696,Unspecified,,,,,Therapeutic index as the ratio of LD50 to that of ED50 values.,Other,4045918.0,
552,237685,4,3,,103164240,3696,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
553,243151,7,2,,103164240,3696,Active,,,3.38844,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
554,243189,7,4,,103164240,3696,Active,7531135.0,3757.0,3.38844,IC50,Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel),Confirmatory,15745831.0,
555,243422,3,10,,103164240,3696,Unspecified,116241312.0,1576.0,,,log (1/Km) value for human liver microsome cytochrome P450 3A4,Other,15990295.0,
556,255079,8,5,,103164240,3696,Active,803374855.0,140.0,0.0044,IC50,Inhibitory concentration against human Adenosine A3 receptor expressed in HEK293 cells using 0.1 nM [3H]AB-MECA,Confirmatory,16250647.0,
557,268084,3,5,,103164240,3696,Unspecified,,,,,Metabolic stability in rat liver microsomes,Other,16647256.0,
558,271644,4,4,,103164240,3696,Active,,,5.0,EC50,Inhibition of protease-resistant scrapie prion protein activity in ScN2a cells,Confirmatory,17064077.0,
559,271645,3,4,,103164240,3696,Active,,,,,Antiprion activity in ScN2a cells assessed as complete reduction of protease-resistant scrapie prion protein,Other,17064077.0,
560,288184,9,1,,103164240,3696,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
561,288185,7,1,,103164240,3696,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
562,288186,3,4,,103164240,3696,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer at 200 rpm stirring speed,Other,17418579.0,
563,288187,3,4,,103164240,3696,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer at 250 rpm stirring speed,Other,17418579.0,
564,288190,3,4,,103164240,3696,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer at 100 rpm stirring speed,Other,17418579.0,
565,288191,3,4,,103164240,3696,Unspecified,,,,,Membrane retention in permeability experiment with artificial membrane,Other,17418579.0,
566,288192,3,4,,103164240,3696,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
567,288193,3,4,,103164240,3696,Unspecified,,,,,"Flux ionization constant, pKa of the membrane permeability coefficient of the compound",Other,17418579.0,
568,288194,3,5,,103164240,3696,Unspecified,,,,,"Intrinsic artificial membrane permeability coefficient, log P0 of the compound",Other,17418579.0,
569,288893,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 10 mg/kg, ip administered 30 mins before the test in forced-swimming test",Other,17517514.0,
570,288894,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 20 mg/kg, ip administered 30 mins before the test in forced-swimming test",Other,17517514.0,
571,288895,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 30 mg/kg, ip administered 30 mins before the test in forced-swimming test",Other,17517514.0,
572,288897,3,3,,103164240,3696,Unspecified,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 10 mg/kg, ip administered 30 mins before the test",Other,17517514.0,
573,288898,3,3,,103164240,3696,Unspecified,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 20 mg/kg, ip administered 30 mins before the test",Other,17517514.0,
574,288901,3,4,,103164240,3696,Unspecified,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 30 mg/kg, ip administered 30 mins before the test",Other,17517514.0,
575,288902,3,3,,103164240,3696,Unspecified,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 5 mg/kg, ip administered 30 mins before the test",Other,17517514.0,
576,288903,3,3,,103164240,3696,Unspecified,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 10 mg/kg, ip administered 30 mins before the test",Other,17517514.0,
577,288907,3,4,,103164240,3696,Unspecified,,,,,"Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 30 mg/kg, ip administered 30 mins before the test",Other,17517514.0,
578,289402,6,2,,103164240,3696,Unspecified,,,244.0,IC50,Displacement of [3H]leucine from Aquifex aeolicus His-LeuT expressed in Escherichia coli by scintillation proximity assay,Confirmatory,17690258.0,
579,293491,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss mouse assessed as immobility time at 15 mg/kg, ip thrice a day by 5-mins swim test",Other,17204426.0,
580,293498,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss mouse assessed as immobility time at 15 mg/kg/day, ip after 10 days by 5-mins swim test",Other,17204426.0,
581,293501,3,3,,103164240,3696,Unspecified,,,,,"Effect on motor co-ordination in Swiss mouse assessed as number of falls at 15 mg/kg, ip after 10 days by Rota-rod test",Other,17204426.0,
582,293504,3,3,,103164240,3696,Unspecified,,,,,"Effect on motor co-ordination in Swiss mouse assessed as time on rotating bar at 15 mg/kg, ip after 10 days by Rota-rod test",Other,17204426.0,
583,294617,4,3,,103164240,3696,Inconclusive,,,,,Antidepressant-like activity in Swiss Albino mouse at 5 mg/kg by forced swimming test,Other,17321139.0,
584,294618,3,3,,103164240,3696,Unspecified,,,,,Antidepressant-like activity in Swiss Albino mouse at 10 mg/kg by forced swimming test,Other,17321139.0,
585,294619,3,3,,103164240,3696,Unspecified,,,,,Antidepressant-like activity in Swiss Albino mouse at 20 mg/kg by forced swimming test,Other,17321139.0,
586,294621,3,3,,103164240,3696,Unspecified,,,,,Antidepressant-like activity in C57BL/6J mouse at 5 mg/kg by tail suspension test,Other,17321139.0,
587,294622,3,3,,103164240,3696,Unspecified,,,,,Antidepressant-like activity in C57BL/6J mouse at 10 mg/kg by tail suspension test,Other,17321139.0,
588,294623,3,3,,103164240,3696,Unspecified,,,,,Antidepressant-like activity in C57BL/6J mouse at 20 mg/kg by tail suspension test,Other,17321139.0,
589,307535,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant effect in mouse at 10 mg/kg, ip assessed as reduction in immobility duration after 30 mins by forced swimming test relative to control",Other,17448659.0,
590,309514,3,3,,103164240,3696,Unspecified,,,,,Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 10 mg/kg administered 30 mins before the test by forced-swimming test,Other,17825569.0,
591,309520,3,3,,103164240,3696,Unspecified,,,,,Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 20 mg/kg administered 30 mins before the test by forced-swimming test,Other,17825569.0,
592,309522,3,3,,103164240,3696,Unspecified,,,,,Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 5 mg/kg administered 30 mins before the test,Other,17825569.0,
593,309524,3,3,,103164240,3696,Unspecified,,,,,Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 10 mg/kg administered 30 mins before the test,Other,17825569.0,
594,309529,3,3,,103164240,3696,Unspecified,,,,,Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 20 mg/kg administered 30 mins before the test,Other,17825569.0,
595,309530,3,3,,103164240,3696,Unspecified,,,,,Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 20 mg/kg administered 30 mins before the test,Other,17825569.0,
596,310931,3,4,,103164240,3696,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17300161.0,
597,311524,4,3,,103164240,3696,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
598,311934,3,3,,103164240,3696,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18027916.0,
599,311935,3,4,,103164240,3696,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18027916.0,
600,329204,6,2,,103164240,3696,Unspecified,,,2090.0,IC50,Inhibition of L-[3H]Leu uptake at Aquifex aeolicus sodium-coupled leucine transporter,Confirmatory,17687333.0,
601,330659,3,3,,103164240,3696,Unspecified,,,,,Effect on life span of Caenorhabditis elegans at 50 uM,Other,18033297.0,
602,330661,3,3,,103164240,3696,Unspecified,,,,,Effect on life span of Caenorhabditis elegans at 200 uM,Other,18033297.0,
603,330664,3,3,,103164240,3696,Unspecified,,,,,Effect on life span of Caenorhabditis elegans at 10 uM,Other,18033297.0,
604,338160,7,3,,103164240,3696,Active,,,0.0203,Ki,Displacement of [3H]citalopram from serotonin transporter,Confirmatory,8496700.0,
605,338197,3,8,,103164240,3696,Unspecified,,,,,Displacement of [3H]citalopram from serotonin transporter assessed as specific binding relative to total binding,Other,8496700.0,
606,343685,3,3,,103164240,3696,Unspecified,,,,,Ratio of drug level in brain to blood in Wistar rat,Other,18558667.0,
607,346472,8,7,,103164240,3696,Active,400630.0,6532.0,,IC50,Displacement of radiolabeled imipramine from human SERT,Confirmatory,18983139.0,
608,349880,8,1,,103164240,3696,Unspecified,,,,,Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA,Other,19374444.0,
609,351887,9,5,,103164240,3696,Active,400630.0,6532.0,0.008,IC50,Inhibition of [3H]5HT uptake at human SERT expressed in HEK293 cells,Confirmatory,17846138.0,
610,351888,9,5,,103164240,3696,Active,266667.0,6531.0,25.6,IC50,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Confirmatory,17846138.0,
611,351894,9,5,,103164240,3696,Active,128616.0,6530.0,0.07400000000000001,IC50,Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells,Confirmatory,17846138.0,
612,360444,4,9,,103164240,3696,Inactive,128613.0,24898.0,,,Displacement of [3H]RTI82 from DAT in rat striatal membrane,Other,17255098.0,
613,361985,3,4,,103164240,3696,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method",Other,18666772.0,
614,361986,3,4,,103164240,3696,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by shake flask method",Other,18666772.0,
615,363878,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in albino mouse assessed as decrease in immobility time at 10 mg/kg, ip after 60 mins by forced-swimming test relative to untreated control",Other,18693019.0,
616,363879,3,3,,103164240,3696,Unspecified,,,,,"Neurotoxicity in albino mouse assessed as animal remained on the revolving rod at 10 mg/kg, ip after 30 mins by rotarod test.",Other,18693019.0,
617,363880,3,3,,103164240,3696,Unspecified,,,,,"Neurotoxicity in albino mouse assessed as animal in lateral position at 10 mg/kg, ip administered 1 hr prior to ethanol challenge measured after 30 mins",Other,18693019.0,
618,373867,6,3,,103164240,3696,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
619,377489,3,3,,103164240,3696,Unspecified,,,,,Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 15 mg/kg during final 4 mins of the 6 mins session by forced swimming test,Other,15787439.0,
620,386623,4,8,,103164240,3696,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
621,386625,9,5,,103164240,3696,Active,313104181.0,6580.0,17.1,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
622,392739,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity against Swiss-Webster mouse assessed as reduction in duration of immobility at 10 mg/kg, ip after 1 hr by tail suspension behavioral despair test relative to control",Other,19147368.0,
623,394126,3,3,,103164240,3696,Unspecified,,,,,"Antidepressive activity in Albino Swiss mouse assessed as total immobility time at 15 mg/kg, ip after 30 mins measured for 4 mins by forced swimming test",Other,18486277.0,
624,395325,3,3,,103164240,3696,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
625,395328,3,3,,103164240,3696,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
626,408340,8,5,,103164240,3696,Active,7531135.0,3757.0,3.38844,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
627,420668,8,5,,103164240,3696,Active,7531135.0,3757.0,3.38844,IC50,Inhibition of human ERG in MCF7 cells,Confirmatory,19110341.0,
628,420669,3,4,,103164240,3696,Unspecified,,,,,"Lipophilicity, log D at pH 7.0",Other,19110341.0,
629,420787,3,10,,103164240,3696,Unspecified,1168222.0,3359.0,,,Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM,Other,19144451.0,
630,425652,7,2,,103164240,3696,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
631,425653,7,2,,103164240,3696,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
632,427196,8,1,,103164240,3696,Unspecified,,,,,Membrane permeability by PAMPA-BBB assay,Other,19663388.0,
633,427197,8,1,,103164240,3696,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay,Other,19663388.0,
634,427198,8,1,,103164240,3696,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay,Other,19663388.0,
635,431484,7,3,,103164240,3696,Active,,,0.00757,Ki,Inhibition of [3H]serotonin reuptake at serotonin transporter,Confirmatory,19791802.0,
636,433879,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss-Webster mouse assessed as reduction in duration of immobility time at 10 mg/kg, ip by tail suspension behavioral despair test",Other,19268406.0,
637,434959,1,1,,85789342,3696,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
638,436830,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant-like activity in NMRI mouse assessed as reduction in immobility time at 16 mg/kg, ip by forced swimming test relative to control",Other,19540762.0,
639,449470,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 10 mg/kg, ip administered 30 mins before test by forced swimming test",Other,19679379.0,
640,449471,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 20 mg/kg, ip administered 30 mins before test by forced swimming test",Other,19679379.0,
641,449472,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 30 mg/kg, ip administered 30 mins before test by forced swimming test",Other,19679379.0,
642,449473,3,3,,103164240,3696,Unspecified,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 20 mg/kg, ip administered 30 mins before test measured for 6 mins",Other,19679379.0,
643,449474,3,3,,103164240,3696,Unspecified,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 20 mg/kg, ip administered 30 mins before test measured for 30 mins",Other,19679379.0,
644,449475,3,3,,103164240,3696,Unspecified,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 30 mg/kg, ip administered 30 mins before test measured for 6 mins",Other,19679379.0,
645,449476,3,3,,103164240,3696,Unspecified,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 30 mg/kg, ip administered 30 mins before test measured for 30 mins",Other,19679379.0,
646,449542,3,3,,103164240,3696,Unspecified,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 10 mg/kg, ip administered 30 mins before test measured for 6 mins",Other,19679379.0,
647,449543,3,3,,103164240,3696,Unspecified,,,,,"Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 10 mg/kg, ip administered 30 mins before test measured for 30 mins",Other,19679379.0,
648,455986,3,5,,103164240,3696,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
649,463106,1,2,,90341377,3696,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
650,467611,3,6,,103164240,3696,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
651,467612,3,6,,103164240,3696,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
652,467613,5,3,,103164240,3696,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
653,469403,5,1,,103164240,3696,Unspecified,,,,,Permeability across PAMPA membrane,Other,19856923.0,
654,476929,3,3,,103164240,3696,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
655,476988,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant-like activity in Swiss mouse assessed as immobilization time at 10 mg/kg, ip after 30 mins by forced swim test (RVb = 167.1 +/- 6.7 s)",Other,20060623.0,
656,476989,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant-like activity in Swiss mouse assessed as immobilization time at 20 mg/kg, ip after 30 mins by forced swim test (RVb = 167.1 +/- 6.7 s)",Other,20060623.0,
657,476994,3,3,,103164240,3696,Unspecified,,,,,"Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 6 mins at 10 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 94.8 +/- 4.1)",Other,20060623.0,
658,476995,3,3,,103164240,3696,Unspecified,,,,,"Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 30 mins at 20 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 94.8 +/- 4.1)",Other,20060623.0,
659,476996,3,3,,103164240,3696,Unspecified,,,,,"Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 30 mins at 10 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 210.7 +/- 17.7)",Other,20060623.0,
660,476997,3,3,,103164240,3696,Unspecified,,,,,"Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 30 mins at 20 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 210.7 +/- 17.7)",Other,20060623.0,
661,478679,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 158.7 +/- 8.9 sec)",Other,20408551.0,
662,478685,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 169.6 +/- 19 sec)",Other,20408551.0,
663,478691,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 150.3 +/- 11.1 sec)",Other,20408551.0,
664,478701,3,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 138.6 +/- 12 sec)",Other,20408551.0,
665,485281,1,1,,11111331,3696,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
666,485290,1,1,,11111331,3696,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
667,485290,1,1,,26751600,3696,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
668,485295,1,2,,90341377,3696,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
669,485297,1,1,,90341377,3696,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
670,485298,1,1,,90341377,3696,Inactive,,,23.1093,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
671,485313,1,2,,90341377,3696,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
672,485342,1,2,,90341377,3696,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
673,485345,1,2,,90341377,3696,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
674,485366,1,2,,90341377,3696,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
675,485368,1,2,,90341377,3696,Inconclusive,72386991.0,3656265.0,37.933,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
676,488772,1,1,,90341377,3696,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
677,488773,1,2,,90341377,3696,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
678,488816,1,1,,90341377,3696,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
679,488837,1,1,,90341377,3696,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
680,488949,1,2,,90341377,3696,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
681,488953,1,1,,90341377,3696,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
682,488978,1,1,,90341377,3696,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
683,488981,1,1,,90341377,3696,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
684,488982,1,1,,90341377,3696,Inactive,4503383.0,1812.0,3.6624,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
685,488983,1,1,,90341377,3696,Active,4503383.0,1812.0,14.1254,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
686,493017,1,1,,103858513,3696,Unspecified,,3762.0,,,Wombat Data for BeliefDocking,Other,12873512.0,
687,493106,1,1,,90341377,3696,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
688,493107,1,1,,90341377,3696,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
689,493153,1,1,,90341377,3696,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
690,493153,1,1,,90341377,3696,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
691,493164,1,2,,90341377,3696,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
692,493164,1,2,,90341377,3696,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
693,493164,1,2,,90341377,3696,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
694,493410,2,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as reduction of immobility duration at 30 mg/kg, ip administered 3 times for 24 hrs measured after 1 hr last post dose by tail suspension test",Other,20580232.0,
695,496020,2,5,,103164240,3696,Unspecified,,,,,Plasma protein binding in human after 30 min by ultrafiltration,Other,19933795.0,
696,496817,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
697,496818,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
698,496819,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
699,496820,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
700,496821,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
701,496823,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
702,496824,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
703,496825,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
704,496826,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
705,496827,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
706,496828,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
707,496829,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
708,496830,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
709,496831,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
710,496832,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
711,497005,4,2,,103164240,3696,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
712,504327,1,1,,11111331,3696,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
713,504327,1,1,,90341377,3696,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
714,504332,1,1,,11111331,3696,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
715,504332,1,1,,90341377,3696,Active,168985070.0,,25.1189,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
716,504536,1,1,,90341377,3696,Inactive,5453898.0,5300.0,10.690999999999999,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
717,504547,1,1,,90341377,3696,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
718,504548,1,2,,90341377,3696,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
719,504749,1,3,,26751600,3696,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
720,504749,1,3,,104171178,3696,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
721,504749,1,3,1.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
722,504749,1,3,2.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
723,504749,1,3,3.0,104171178,3696,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
724,504749,1,3,4.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
725,504749,1,3,5.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
726,504749,1,3,6.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
727,504749,1,3,7.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
728,504749,1,3,8.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
729,504749,1,3,9.0,104171178,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
730,504749,1,3,10.0,26751600,3696,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
731,504749,1,3,11.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
732,504749,1,3,12.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
733,504749,1,3,13.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
734,504749,1,3,14.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
735,504749,1,3,15.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
736,504749,1,3,16.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
737,504749,1,3,17.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
738,504749,1,3,18.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
739,504749,1,3,19.0,26751600,3696,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
740,504749,1,3,20.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
741,504749,1,3,21.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
742,504749,1,3,22.0,104171178,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
743,504749,1,3,23.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
744,504749,1,3,24.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
745,504749,1,3,25.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
746,504749,1,3,26.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
747,504749,1,3,27.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
748,504749,1,3,28.0,104171178,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
749,504749,1,3,29.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
750,504749,1,3,30.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
751,504749,1,3,31.0,104171178,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
752,504749,1,3,32.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
753,504749,1,3,33.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
754,504749,1,3,34.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
755,504749,1,3,35.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
756,504749,1,3,36.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
757,504749,1,3,37.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
758,504749,1,3,38.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
759,504749,1,3,39.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
760,504749,1,3,40.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
761,504749,1,3,41.0,104171178,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
762,504749,1,3,42.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
763,504749,1,3,43.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
764,504749,1,3,44.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
765,504749,1,3,45.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
766,504749,1,3,46.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
767,504749,1,3,47.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
768,504749,1,3,48.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
769,504749,1,3,49.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
770,504749,1,3,50.0,104171178,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
771,504749,1,3,51.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
772,504749,1,3,52.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
773,504749,1,3,53.0,104171178,3696,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
774,504749,1,3,54.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
775,504749,1,3,55.0,104171178,3696,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
776,504749,1,3,56.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
777,504749,1,3,57.0,26751600,3696,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
778,504749,1,3,58.0,26751600,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
779,504749,1,3,59.0,104171178,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
780,504749,1,3,60.0,104171178,3696,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
781,504749,1,3,61.0,26751600,3696,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
782,504810,1,2,,90341377,3696,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
783,504812,1,2,,90341377,3696,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
784,504832,1,1,,104171178,3696,Inconclusive,,,16.9441,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
785,504834,1,1,,104171178,3696,Active,,,3.7933,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
786,504836,1,2,,90341377,3696,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
787,504845,1,1,,90341377,3696,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
788,504845,1,1,,104171178,3696,Inconclusive,86301163.0,5999.0,0.9466,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
789,504847,1,1,,11111331,3696,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
790,504847,1,1,,90341377,3696,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
791,504847,1,1,,104171178,3696,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
792,504865,1,1,,11111331,3696,Inconclusive,118600387.0,7398.0,35.4813,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
793,504865,1,1,,90341377,3696,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
794,504865,1,1,,104171178,3696,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
795,515780,5,1,,103164240,3696,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
796,540209,4,3,,103164240,3696,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
797,540210,4,3,,103164240,3696,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
798,540211,2,5,,103164240,3696,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
799,540212,4,3,,103164240,3696,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
800,540213,4,3,,103164240,3696,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
801,540234,2,5,,103164240,3696,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
802,540237,2,3,,103164240,3696,Active,,,,,Phospholipidosis-positive literature compound observed in rat,Other,17428028.0,
803,540256,1,2,,90341377,3696,Inconclusive,,,1.2990000000000002,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
804,540276,1,2,,11111330,3696,Inconclusive,420597.0,,11.5821,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
805,540276,1,2,,11111331,3696,Inconclusive,420597.0,,11.5821,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
806,540276,1,2,,26751600,3696,Inconclusive,420597.0,,11.5821,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
807,540276,1,2,,50100256,3696,Inconclusive,420597.0,,11.5821,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
808,540276,1,2,,50104254,3696,Inconclusive,420597.0,,11.5821,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
809,540276,1,2,,90341377,3696,Active,420597.0,,12.99,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
810,540276,1,2,,104171178,3696,Inconclusive,420597.0,,11.5821,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
811,566273,6,5,,103164240,3696,Active,400630.0,6532.0,0.0073,IC50,Inhibition of human 5-HT transporter,Confirmatory,20875743.0,
812,576612,7,5,,103164240,3696,Active,7531135.0,3757.0,3.38844,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
813,581672,7,1,,103164240,3696,Active,,,22.0,IC50,Inhibition of Pdr5p-mediated rhodamine 6G transport in Saccharomyces cerevisiae MKPDR5h plasma membrane by spectrofluorometric assay,Confirmatory,19188399.0,
814,581806,4,1,,103164240,3696,Unspecified,,,,,Inhibition of Saccharomyces cerevisiae MKPDR5h multidrug transporter Pdr5p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening spectrofluorometric assay,Other,19188399.0,
815,581807,4,1,,103164240,3696,Unspecified,,,,,Inhibition of Saccharomyces cerevisiae MKCDR1h multidrug transporter Cdr1p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening spectrofluorometric assay,Other,19188399.0,
816,581808,4,1,,103164240,3696,Unspecified,,,,,Inhibition of Saccharomyces cerevisiae MKSNQ2h multidrug transporter Snq2p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening spectrofluorometric assay,Other,19188399.0,
817,588208,2,3,,103164240,3696,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
818,588211,2,3,,103164240,3696,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
819,588212,2,3,,103164240,3696,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
820,588213,2,3,,103164240,3696,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
821,588220,2,3,,103164240,3696,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
822,588349,1,1,,90341377,3696,Inconclusive,,,28.1838,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
823,588378,1,1,,90341377,3696,Inconclusive,171543895.0,6311.0,28.1838,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
824,588453,1,1,,90341377,3696,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
825,588456,1,1,,90341377,3696,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
826,588579,1,1,,11111331,3696,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
827,588579,1,1,,90341377,3696,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
828,588579,1,1,,104171178,3696,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
829,588795,1,1,,90341377,3696,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
830,588834,2,1,,26751600,3696,Active,325651834.0,3757.0,15.8489,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
831,589038,1,10,,103164240,3696,Unspecified,84028191.0,1565.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP2D6",Other,,
832,590293,1,3,,103164240,3696,Active,,,,,"Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time at 30 mg/kg, ip measured for 6 mins by forced swim test",Other,21377878.0,
833,590299,1,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as decrease in immobility duration at 30 mg/kg, ip administered 30 mins prior to test measured after 30 mins by tail suspension test (Rvb = 79.9%)",Other,21377878.0,
834,592681,1,4,,103164240,3696,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
835,596125,1,3,,103164240,3696,Active,,,,,"Antidepressant activity in Swiss Sprague-Dawley rat assessed as reduction of immobility time at 15 mg/kg, ip administered 30 mins before test by forced swimming test",Other,21446715.0,
836,598090,1,3,,103164240,3696,Active,,,,,"Antidepressant-like activity in mouse assessed as immobility time at 20 mg/kg, ip after 30 mins by forced swim test",Other,21524576.0,
837,598094,1,4,,103164240,3696,Inconclusive,,,,,"Plasma concentration in mouse at 20 mg/kg, ip after 30 mins",Other,21524576.0,
838,598130,1,4,,103164240,3696,Inconclusive,,,,,"Drug level in mouse brain at 20 mg/kg, ip after 30 mins",Other,21524576.0,
839,598134,1,5,,103164240,3696,Inconclusive,,,,,"Ratio of drug level in brain to plasma in mouse at 20 mg/kg, ip after 30 mins",Other,21524576.0,
840,602332,1,1,,11111331,3696,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
841,602332,1,1,,90341377,3696,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
842,602332,1,1,,104171178,3696,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
843,603953,1,3,,103164240,3696,Unspecified,,,,,"In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
844,611034,1,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss mouse assessed as reduction of immobility duration at 10 mg/kg, ip administered 30 mins prior test measured during last 4 mins of 6 mins observation period by forced-swimming test (Rvb = 0 %)",Other,21696965.0,
845,611038,1,3,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss mouse assessed as immobility duration at 10 mg/kg, ip administered 30 mins prior test measured during last 4 mins of 6 mins observation period by forced-swimming test (Rvb = 166 +/- 12.23 to 218.54 +/- 8.11 Secs)",Other,21696965.0,
846,612016,4,5,,103164240,3696,Active,400630.0,6532.0,0.0007700000000000001,Ki,Displacement of [3H]imipramine from human 5HT transporter,Confirmatory,21726069.0,
847,620399,3,1,,103164240,3696,Unspecified,,,,,Permeability of the compound by PAMPA,Other,21871694.0,
848,624030,1,2,,104171178,3696,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
849,624031,1,2,,104171178,3696,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
850,624032,1,2,,104171178,3696,Inconclusive,8393992.0,24660.0,40.5334,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
851,624044,1,2,,104171178,3696,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
852,624146,1,1,,90341377,3696,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
853,624147,1,1,,90341377,3696,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
854,624148,1,2,,90341377,3696,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
855,624149,1,1,,90341377,3696,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
856,624156,1,1,,85789342,3696,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
857,624170,1,1,,104171178,3696,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
858,624172,1,1,,104171178,3696,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
859,624173,1,3,,104171178,3696,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
860,624296,1,1,,26751600,3696,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
861,624296,1,1,,104171178,3696,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
862,624297,1,1,,26751600,3696,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
863,624297,1,1,,104171178,3696,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
864,624349,1,2,,92308804,3696,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
865,624455,1,1,,90341377,3696,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
866,624606,1,9,,103164240,3696,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
867,624607,1,9,,103164240,3696,Unspecified,549152.0,54659.0,,,Specific activity of expressed human recombinant UGT1A3,Other,10836148.0,
868,624608,3,2,,103164240,3696,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
869,624609,1,9,,103164240,3696,Unspecified,29840832.0,54578.0,,,Specific activity of expressed human recombinant UGT1A6,Other,10836148.0,
870,624610,1,9,,103164240,3696,Unspecified,30173486.0,54577.0,,,Specific activity of expressed human recombinant UGT1A7,Other,10836148.0,
871,624611,1,9,,103164240,3696,Unspecified,29839637.0,54576.0,,,Specific activity of expressed human recombinant UGT1A8,Other,10836148.0,
872,624612,1,9,,103164240,3696,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
873,624613,1,9,,103164240,3696,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
874,624615,1,8,,103164240,3696,Unspecified,549155.0,7365.0,,,Specific activity of expressed human recombinant UGT2B10,Other,10836148.0,
875,624616,1,8,,103164240,3696,Unspecified,332278237.0,7366.0,,,Specific activity of expressed human recombinant UGT2B15,Other,10836148.0,
876,624617,1,8,,103164240,3696,Unspecified,6136104.0,7367.0,,,Specific activity of expressed human recombinant UGT2B17,Other,10836148.0,
877,624618,3,2,,103164240,3696,Unspecified,6175083.0,7363.0,,,Specific activity of expressed human recombinant UGT2B4,Other,10836148.0,
878,624632,3,7,,103164240,3696,Unspecified,549152.0,54659.0,472.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A3,Confirmatory,15781124.0,
879,624633,3,7,,103164240,3696,Unspecified,136731.0,54657.0,310.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A4,Confirmatory,15781124.0,
880,625277,1,3,,103164240,3696,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
881,625279,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
882,625280,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
883,625281,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
884,625282,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
885,625283,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
886,625284,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
887,625285,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
888,625286,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
889,625287,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
890,625288,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
891,625289,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
892,625290,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
893,625291,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
894,625292,1,3,,103164240,3696,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
895,639368,3,1,,103164240,3696,Unspecified,,,,,Permeability of the compound by PAMPA assay,Other,21420206.0,
896,643383,1,6,,103164240,3696,Unspecified,,,,,Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy,Other,22122484.0,
897,648667,3,1,,103164240,3696,Unspecified,,,,,Permeability of the compound in porcine brain lipid assessed as ratio of compound in acceptor plate to amount of compound in donor plate at 5 mg/ml after 10 hrs by PAMPA assay,Other,22341944.0,
898,651631,4,1,,144203725,3696,Inconclusive,269849759.0,7157.0,13.3332,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
899,651632,4,1,,144203725,3696,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
900,651633,4,1,,144203725,3696,Inactive,,,0.7498,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
901,651634,4,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
902,651635,1,3,,11111331,3696,Inconclusive,171543895.0,6311.0,11.2202,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
903,651635,1,3,,90341377,3696,Inconclusive,171543895.0,6311.0,28.1838,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
904,651741,1,1,,124880469,3696,Inconclusive,20149576.0,4780.0,30.6379,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
905,651828,1,2,,92308804,3696,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
906,652048,1,2,,144203725,3696,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
907,652051,1,1,,144203725,3696,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
908,652106,1,1,,90341377,3696,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
909,676720,1,2,,103164240,3696,Active,,,,,"Antidepressant activity in CF1 mouse assessed as reduction in immobility at 20 mg/kg, po measured after 60 mins by forced-swimming test",Other,22686708.0,
910,678712,1,8,,103164240,3696,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
911,678713,1,8,,103164240,3696,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
912,678714,1,8,,103164240,3696,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
913,678715,1,8,,103164240,3696,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
914,678716,1,8,,103164240,3696,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
915,678717,1,8,,103164240,3696,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
916,678719,1,5,,103164240,3696,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
917,678722,1,5,,103164240,3696,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
918,679763,1,8,,103164240,3696,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Imipramine: 100 uM) in MDR1-expressing MDCKII cells",Other,12438524.0,
919,680295,1,8,,103164240,3696,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Imipramine: 20 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
920,681116,1,8,,103164240,3696,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells,Other,12438524.0,
921,681118,1,8,,103164240,3696,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco-2 cells,Other,12954186.0,
922,681345,3,6,,103164240,3696,Unspecified,81872789.0,29503.0,9.9,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM) in OCT2-expressing MDCK cells,Confirmatory,11758759.0,
923,681348,3,6,,103164240,3696,Unspecified,81872095.0,24904.0,16.0,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM) in OCT1-expressing MDCK cells,Confirmatory,11758759.0,
924,681443,1,7,,103164240,3696,Unspecified,50401224.0,64037.0,,,TP_TRANSPORTER: inhibition of TEA uptake by Imipramine at 1mM in Octn1-HRPE cells,Other,10825452.0,
925,681584,3,6,,103164240,3696,Unspecified,24212063.0,6581.0,42.0,Ki,TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HRPE cells,Confirmatory,10966924.0,
926,681985,1,7,,103164240,3696,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Imipramine: 1000 uM) in OCT2A-expressing HEK293 cells",Other,12089365.0,
927,681986,1,7,,103164240,3696,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Imipramine: 1000 uM) in OCT2-expressing HEK293 cells",Other,12089365.0,
928,686977,2,1,,49698865,3696,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
929,686978,1,1,,144203725,3696,Inconclusive,79154014.0,55775.0,13.3359,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
930,686979,1,1,,144203725,3696,Active,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
931,692183,1,2,,103164240,3696,Unspecified,,,,,Protein binding in human plasma,Other,21599003.0,
932,692184,1,2,,103164240,3696,Inconclusive,,,,,"Therapeutic index, ratio of Cmax in human to IC50 for human MATE2-K",Other,21599003.0,
933,692185,2,3,,103164240,3696,Active,,,,,Cmax in human,Other,21599003.0,
934,692186,1,2,,103164240,3696,Unspecified,,,,,"Therapeutic index, ratio of Cmax in human to IC50 for human OCT1",Other,21599003.0,
935,692187,1,2,,103164240,3696,Unspecified,,,,,"Therapeutic index, ratio of Cmax in human to IC50 for human MATE1",Other,21599003.0,
936,692188,1,2,,103164240,3696,Unspecified,,,,,"Therapeutic index, ratio of Cmax in human to IC50 for human OCT2",Other,21599003.0,
937,692189,1,2,,103164240,3696,Unspecified,,,,,"Therapeutic index, ratio of Cmax in human to IC50 for human OCT2 A270S mutant",Other,21599003.0,
938,692192,2,7,,103164240,3696,Active,313104182.0,6582.0,0.6,IC50,Inhibition of human OCT2 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay,Confirmatory,21599003.0,
939,692193,2,2,,103164240,3696,Active,,,2.1,IC50,Inhibition of human OCT2 A270S mutant expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay,Confirmatory,21599003.0,
940,692194,2,7,,103164240,3696,Active,313104181.0,6580.0,37.0,IC50,Inhibition of human OCT1 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay,Confirmatory,21599003.0,
941,692195,2,7,,103164240,3696,Active,74731723.0,55244.0,10.0,IC50,Inhibition of human MATE1 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay,Confirmatory,21599003.0,
942,692196,2,7,,103164240,3696,Unspecified,74727585.0,146802.0,100.0,IC50,Inhibition of human MATE2-K expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay,Confirmatory,21599003.0,
943,699539,1,7,,103164240,3696,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
944,699540,1,7,,103164240,3696,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
945,699541,1,7,,103164240,3696,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
946,714926,1,2,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as mean immobility time measured during 6 mins period at 20 mg/kg, po administered 30 mins before test by tail suspension test (Rvb = 185.7 +/- 5.33 secs)",Other,23079521.0,
947,714927,1,2,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as mean immobility time measured during last 4 mins of single 6 mins test session at 20 mg/kg, po by forced swim test (Rvb = 75.33 +/- 3.35 secs)",Other,23079521.0,
948,720516,2,1,,144203725,3696,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
949,720532,1,1,,11111331,3696,Active,420597.0,,7.0795,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
950,720532,1,1,,144203725,3696,Active,420597.0,,11.2202,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
951,720533,1,1,,11111331,3696,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
952,720533,1,1,,144203725,3696,Inconclusive,,,31.6228,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
953,720538,1,2,,90341377,3696,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
954,720552,2,1,,144203725,3696,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
955,720559,1,2,,90341377,3696,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
956,720572,1,2,,90341377,3696,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
957,720573,1,2,,90341377,3696,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
958,720634,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
959,720635,2,1,,144203725,3696,Inconclusive,,,8.4127,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
960,720636,1,1,,124880469,3696,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
961,720637,2,1,,144203725,3696,Inconclusive,,,19.5704,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
962,720641,1,2,,92308804,3696,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
963,720674,2,2,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
964,720675,2,2,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
965,720678,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
966,720679,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
967,720680,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
968,720681,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
969,720682,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
970,720683,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
971,720684,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
972,720685,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
973,720686,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
974,720687,2,2,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
975,720691,4,1,,144203725,3696,Inactive,311348376.0,2908.0,18.9959,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
976,720692,3,1,,144203725,3696,Inconclusive,311348376.0,2908.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
977,720693,3,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
978,720717,1,3,,92308804,3696,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
979,720719,2,1,,144203725,3696,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
980,720725,2,1,,144203725,3696,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
981,729797,2,5,,103164240,3696,Active,400630.0,6532.0,0.028999999999999998,IC50,Inhibition of human SERT expressed in HEK293-MSR cells by 5-HT uptake assay,Confirmatory,23385211.0,
982,729812,1,2,,103164240,3696,Inactive,,,,,Induction of apoptosis in human HeLa cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay,Other,23385211.0,
983,729813,1,3,,103164240,3696,Inactive,,,,,Induction of apoptosis in human DG75 cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay,Other,23385211.0,
984,729814,1,2,,103164240,3696,Inactive,,,,,Induction of apoptosis in human MUTU-I cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay,Other,23385211.0,
985,729819,1,2,,103164240,3696,Active,,,40.74,IC50,Reduction in cell viability of human HeLa cells after 24 hrs by Alamar blue viability assay,Confirmatory,23385211.0,
986,729820,1,3,,103164240,3696,Unspecified,,,50.0,IC50,Reduction in cell viability of human DG75 cells after 24 hrs by Alamar blue viability assay,Confirmatory,23385211.0,
987,729821,1,3,,103164240,3696,Active,,,14.12,IC50,Reduction in cell viability of human MUTU-I cells after 24 hrs by Alamar blue viability assay,Confirmatory,23385211.0,
988,743012,3,1,,144203725,3696,Active,,,13.3332,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
989,743014,3,1,,144203725,3696,Active,,,23.7101,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
990,743015,3,1,,144203725,3696,Active,,,29.8493,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
991,743033,3,1,,144203725,3696,Inconclusive,,,3.378,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
992,743035,2,1,,144203725,3696,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
993,743036,2,1,,144203725,3696,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
994,743040,3,1,,144203725,3696,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
995,743041,3,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
996,743042,3,1,,144203725,3696,Inconclusive,124375976.0,367.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
997,743053,2,1,,144203725,3696,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
998,743054,2,1,,144203725,3696,Inconclusive,124375976.0,367.0,31.618000000000002,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
999,743063,2,1,,144203725,3696,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1000,743064,3,1,,144203725,3696,Active,,,5.9557,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1001,743065,3,1,,144203725,3696,Active,399498506.0,24831.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1002,743066,3,1,,144203725,3696,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1003,743067,2,1,,144203725,3696,Inconclusive,399498506.0,24831.0,25.1151,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1004,743069,2,1,,144203725,3696,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1005,743074,2,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1006,743075,2,1,,144203725,3696,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1007,743077,2,1,,144203725,3696,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1008,743078,2,1,,144203725,3696,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1009,743079,3,1,,144203725,3696,Inconclusive,348019627.0,2099.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1010,743080,3,1,,144203725,3696,Inconclusive,348019627.0,2099.0,188.33599999999998,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1011,743081,3,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1012,743083,3,1,,144203725,3696,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1013,743084,3,1,,144203725,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1014,743085,3,1,,144203725,3696,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1015,743086,3,1,,144203725,3696,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1016,743091,2,1,,144203725,3696,Inconclusive,348019627.0,2099.0,79.4208,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1017,743094,3,1,,144203725,3696,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1018,743122,2,1,,144203725,3696,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1019,743139,2,1,,144203725,3696,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1020,743140,2,1,,144203725,3696,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1021,743191,3,1,,170464777,3696,Inconclusive,216409692.0,5468.0,14.9589,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1022,743194,3,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1023,743199,2,1,,170464777,3696,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1024,743202,4,1,,170464777,3696,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1025,743203,3,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1026,743205,1,1,,90341377,3696,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1027,743205,1,1,,90341377,3696,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1028,743206,1,1,,90341377,3696,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1029,743206,1,1,,90341377,3696,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1030,743207,1,1,,90341377,3696,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1031,743207,1,1,,90341377,3696,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1032,743209,3,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1033,743210,4,1,,170464777,3696,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1034,743211,3,1,,170464777,3696,Inconclusive,,,26.6011,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1035,743212,3,1,,170464777,3696,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1036,743213,3,1,,170464777,3696,Active,,,26.6011,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1037,743215,3,1,,170464777,3696,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1038,743217,3,1,,170464777,3696,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1039,743218,3,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1040,743219,3,1,,170464777,3696,Inconclusive,20149576.0,4780.0,28.1774,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1041,743220,3,1,,170464777,3696,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1042,743221,3,1,,170464777,3696,Inconclusive,,,10.5901,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1043,743222,3,1,,170464777,3696,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1044,743223,3,1,,170464777,3696,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1045,743224,3,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1046,743225,3,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1047,743226,2,1,,170464777,3696,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1048,743227,2,1,,170464777,3696,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1049,743228,3,1,,170464777,3696,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1050,743239,2,1,,170464777,3696,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1051,743240,2,1,,170464777,3696,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1052,743241,2,1,,170464777,3696,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1053,743242,2,1,,170464777,3696,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1054,743244,1,1,,90341377,3696,Active,,,1.2589,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1055,743244,1,1,,144203725,3696,Inconclusive,,,12.5893,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1056,751835,2,3,,103164240,3696,Active,400630.0,6532.0,,IC50,Binding affinity to human 5-HT transporter by radioligand displacement assay,Confirmatory,23466604.0,
1057,752199,2,3,,103164240,3696,Active,400630.0,6532.0,0.002,IC50,Binding affinity to human serotonin 5-HT transporter by radioligand displacement assay,Confirmatory,23582449.0,
1058,773434,2,3,,103164240,3696,Active,400630.0,6532.0,0.0068,IC50,Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells,Confirmatory,24012181.0,
1059,775111,1,1,,103164240,3696,Active,,,,,"Antidepressant activity in ICR mouse assessed as immobility time at 20 mg/kg, ip by tail suspension test",Other,24035337.0,
1060,780292,1,1,,103164240,3696,Active,,,,,"Effect on social seperation in chick anxiety-depression model assessed as attenuation of decline in distress vocalizations during depression-like phase at 5 mg/kg, ip 15 mins prior to behavioral testing measured after 45 to 60 mins",Other,24084296.0,
1061,780294,1,1,,103164240,3696,Active,,,,,"Effect on social seperation in chick anxiety-depression model assessed as attenuation of decline in distress vocalizations during depression-like phase at 5 mg/kg, ip 15 mins prior to behavioral testing measured after 30 to 45 mins",Other,24084296.0,
1062,780297,1,1,,103164240,3696,Active,,,,,"Effect on isolation-stressor in chick anxiety-depression model assessed as attenuation of decline in distress vocalizations during depression-like phase at 5 mg/kg, ip 15 mins prior to behavioral testing measured after 5 to 60 mins",Other,24084296.0,
1063,781326,1,2,,103164240,3696,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
1064,781328,1,2,,103164240,3696,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
1065,895490,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/14,Other,,
1066,895491,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/14,Other,,
1067,895492,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/14,Other,,
1068,895493,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/14,Other,,
1069,895494,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/14,Other,,
1070,895535,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/10,Other,,
1071,895536,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/10,Other,,
1072,895537,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/10,Other,,
1073,895538,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/10,Other,,
1074,895539,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/10,Other,,
1075,895540,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/10,Other,,
1076,895541,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/10,Other,,
1077,895542,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/10,Other,,
1078,895543,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/10,Other,,
1079,895544,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/10,Other,,
1080,895545,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/10,Other,,
1081,895546,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/10,Other,,
1082,895547,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/10,Other,,
1083,895548,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/10,Other,,
1084,895549,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/11,Other,,
1085,895550,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/11,Other,,
1086,895551,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/11,Other,,
1087,895552,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/11,Other,,
1088,895553,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/11,Other,,
1089,895554,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/11,Other,,
1090,895555,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/11,Other,,
1091,895556,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/11,Other,,
1092,895557,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/11,Other,,
1093,895558,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/11,Other,,
1094,895559,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/11,Other,,
1095,895560,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/11,Other,,
1096,895561,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/11,Other,,
1097,895562,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/11,Other,,
1098,895563,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/11,Other,,
1099,895564,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/11,Other,,
1100,895565,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/11,Other,,
1101,895566,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/11,Other,,
1102,895567,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/11,Other,,
1103,895568,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/11,Other,,
1104,895569,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/11,Other,,
1105,896392,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/5,Other,,
1106,896393,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/5,Other,,
1107,896394,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/5,Other,,
1108,896395,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/5,Other,,
1109,896396,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/5,Other,,
1110,896397,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/5,Other,,
1111,897075,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/5,Other,,
1112,897076,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/5,Other,,
1113,897077,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/5,Other,,
1114,897078,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/5,Other,,
1115,897079,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/5,Other,,
1116,897080,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/5,Other,,
1117,897081,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/5,Other,,
1118,897082,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/5,Other,,
1119,897083,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/5,Other,,
1120,897084,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/5,Other,,
1121,897085,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/5,Other,,
1122,897086,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/5,Other,,
1123,897677,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/15,Other,,
1124,897678,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/15,Other,,
1125,897679,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/15,Other,,
1126,897680,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/15,Other,,
1127,897681,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/15,Other,,
1128,897682,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/15,Other,,
1129,897683,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/15,Other,,
1130,897684,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/15,Other,,
1131,897685,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/15,Other,,
1132,897686,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/15,Other,,
1133,897687,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/15,Other,,
1134,897688,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/15,Other,,
1135,897689,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/15,Other,,
1136,897690,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/15,Other,,
1137,897691,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/15,Other,,
1138,897692,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/15,Other,,
1139,897693,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/15,Other,,
1140,897694,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/15,Other,,
1141,897695,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/15,Other,,
1142,897696,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/15,Other,,
1143,897697,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/15,Other,,
1144,897698,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/16,Other,,
1145,897699,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/16,Other,,
1146,897700,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/16,Other,,
1147,897701,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/16,Other,,
1148,897702,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/16,Other,,
1149,897703,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/16,Other,,
1150,897704,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/16,Other,,
1151,897705,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/16,Other,,
1152,897706,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/16,Other,,
1153,897707,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/16,Other,,
1154,897708,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/16,Other,,
1155,897709,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/16,Other,,
1156,897710,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/16,Other,,
1157,897711,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/16,Other,,
1158,897755,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/12,Other,,
1159,897756,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/12,Other,,
1160,897757,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/12,Other,,
1161,898392,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/16,Other,,
1162,898393,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/16,Other,,
1163,898394,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/16,Other,,
1164,898395,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/16,Other,,
1165,898396,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/16,Other,,
1166,898397,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/16,Other,,
1167,898398,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/16,Other,,
1168,898399,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/5,Other,,
1169,898400,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/5,Other,,
1170,898401,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/5,Other,,
1171,898402,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/5,Other,,
1172,898403,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/5,Other,,
1173,898404,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/5,Other,,
1174,898438,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/12,Other,,
1175,898439,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/12,Other,,
1176,898440,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/12,Other,,
1177,898441,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/12,Other,,
1178,898442,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/12,Other,,
1179,898443,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/12,Other,,
1180,898444,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/12,Other,,
1181,898445,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/12,Other,,
1182,898446,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/12,Other,,
1183,898447,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/12,Other,,
1184,898448,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/12,Other,,
1185,898449,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/12,Other,,
1186,898450,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/12,Other,,
1187,898451,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/12,Other,,
1188,898452,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/12,Other,,
1189,898453,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/12,Other,,
1190,898454,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/12,Other,,
1191,898455,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/12,Other,,
1192,898456,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/13,Other,,
1193,898457,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/13,Other,,
1194,898458,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/13,Other,,
1195,898459,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/13,Other,,
1196,898460,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/13,Other,,
1197,898461,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/13,Other,,
1198,898462,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/13,Other,,
1199,898463,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/13,Other,,
1200,898464,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/13,Other,,
1201,898465,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/13,Other,,
1202,898466,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/13,Other,,
1203,898467,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/13,Other,,
1204,898468,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/13,Other,,
1205,898469,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/13,Other,,
1206,898470,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/13,Other,,
1207,898471,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/13,Other,,
1208,898472,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/13,Other,,
1209,898473,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/13,Other,,
1210,898474,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/13,Other,,
1211,898475,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/13,Other,,
1212,898476,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/13,Other,,
1213,898477,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/14,Other,,
1214,898478,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/14,Other,,
1215,898479,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/14,Other,,
1216,898480,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/14,Other,,
1217,898481,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/14,Other,,
1218,899274,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/5,Other,,
1219,899275,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/5,Other,,
1220,899276,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/5,Other,,
1221,899277,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/6,Other,,
1222,899278,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/6,Other,,
1223,899279,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/6,Other,,
1224,899280,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/6,Other,,
1225,899281,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/6,Other,,
1226,899282,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/6,Other,,
1227,899283,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/6,Other,,
1228,899284,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/6,Other,,
1229,899285,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/6,Other,,
1230,899286,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/6,Other,,
1231,899287,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/6,Other,,
1232,899288,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/6,Other,,
1233,899289,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/6,Other,,
1234,899290,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/6,Other,,
1235,899291,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/6,Other,,
1236,899292,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/6,Other,,
1237,899293,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/6,Other,,
1238,899294,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/6,Other,,
1239,899295,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/6,Other,,
1240,899296,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/6,Other,,
1241,899297,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/6,Other,,
1242,899298,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/7,Other,,
1243,899299,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/7,Other,,
1244,899300,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/7,Other,,
1245,899301,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/7,Other,,
1246,899978,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/7,Other,,
1247,899979,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/7,Other,,
1248,899980,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/7,Other,,
1249,899981,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/7,Other,,
1250,899982,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/7,Other,,
1251,899983,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/7,Other,,
1252,899984,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/7,Other,,
1253,899985,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/7,Other,,
1254,899986,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/7,Other,,
1255,899987,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/7,Other,,
1256,899988,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/7,Other,,
1257,899989,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/7,Other,,
1258,899990,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/7,Other,,
1259,899991,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/7,Other,,
1260,899992,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/7,Other,,
1261,899993,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/7,Other,,
1262,899994,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/7,Other,,
1263,899995,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/8,Other,,
1264,899996,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/8,Other,,
1265,899997,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/8,Other,,
1266,900587,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/5,Other,,
1267,900588,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/5,Other,,
1268,900589,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/5,Other,,
1269,900590,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/5,Other,,
1270,900591,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/5,Other,,
1271,900592,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/5,Other,,
1272,900593,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/5,Other,,
1273,900594,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/5,Other,,
1274,900595,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/5,Other,,
1275,900596,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/5,Other,,
1276,900597,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/5,Other,,
1277,900598,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/5,Other,,
1278,900599,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/5,Other,,
1279,900600,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/5,Other,,
1280,900601,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/5,Other,,
1281,900602,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/6,Other,,
1282,900603,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/6,Other,,
1283,900604,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/6,Other,,
1284,900605,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/6,Other,,
1285,900606,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/6,Other,,
1286,900607,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/6,Other,,
1287,900608,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/6,Other,,
1288,900609,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/6,Other,,
1289,900610,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/6,Other,,
1290,900611,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/6,Other,,
1291,900612,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/6,Other,,
1292,900614,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/6,Other,,
1293,900615,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/6,Other,,
1294,901294,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/6,Other,,
1295,901295,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/6,Other,,
1296,901296,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/6,Other,,
1297,901297,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/6,Other,,
1298,901298,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/6,Other,,
1299,901299,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/6,Other,,
1300,901300,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/6,Other,,
1301,901301,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/6,Other,,
1302,901302,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/7,Other,,
1303,901303,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/7,Other,,
1304,901304,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/7,Other,,
1305,901305,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/7,Other,,
1306,901306,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/7,Other,,
1307,901307,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/7,Other,,
1308,901308,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/7,Other,,
1309,901309,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/7,Other,,
1310,901310,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/7,Other,,
1311,901311,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/7,Other,,
1312,901312,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/7,Other,,
1313,901345,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/14,Other,,
1314,901346,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/14,Other,,
1315,901347,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/14,Other,,
1316,901348,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/14,Other,,
1317,901349,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/14,Other,,
1318,901350,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/14,Other,,
1319,901351,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/14,Other,,
1320,901352,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/14,Other,,
1321,901353,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/14,Other,,
1322,901354,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/14,Other,,
1323,901355,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/14,Other,,
1324,901356,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/14,Other,,
1325,901357,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/14,Other,,
1326,901358,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/14,Other,,
1327,901359,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/14,Other,,
1328,901360,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/14,Other,,
1329,901361,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/15,Other,,
1330,901362,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/15,Other,,
1331,901363,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/15,Other,,
1332,901364,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/15,Other,,
1333,901365,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/15,Other,,
1334,901366,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/15,Other,,
1335,901367,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/15,Other,,
1336,901368,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/15,Other,,
1337,901369,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/15,Other,,
1338,901370,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/15,Other,,
1339,901371,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/15,Other,,
1340,901372,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/15,Other,,
1341,901373,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/15,Other,,
1342,901374,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/15,Other,,
1343,901375,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/15,Other,,
1344,901376,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/15,Other,,
1345,901377,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/15,Other,,
1346,901378,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/15,Other,,
1347,901379,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/15,Other,,
1348,901380,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/15,Other,,
1349,901381,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/15,Other,,
1350,901382,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/16,Other,,
1351,901383,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/16,Other,,
1352,901384,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/16,Other,,
1353,902069,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/16,Other,,
1354,902070,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/16,Other,,
1355,902071,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/16,Other,,
1356,902072,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/16,Other,,
1357,902073,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/16,Other,,
1358,902074,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/16,Other,,
1359,902075,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/16,Other,,
1360,902186,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/8,Other,,
1361,902187,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/8,Other,,
1362,902188,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/8,Other,,
1363,902189,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/8,Other,,
1364,902190,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/8,Other,,
1365,902191,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/8,Other,,
1366,902192,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/8,Other,,
1367,902193,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/8,Other,,
1368,902194,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/8,Other,,
1369,902195,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/8,Other,,
1370,902196,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/8,Other,,
1371,902197,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/8,Other,,
1372,902198,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/8,Other,,
1373,902199,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/8,Other,,
1374,902200,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/8,Other,,
1375,902201,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/8,Other,,
1376,902202,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/8,Other,,
1377,902203,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/8,Other,,
1378,902204,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/9,Other,,
1379,902741,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/10,Other,,
1380,902742,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/10,Other,,
1381,902743,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/10,Other,,
1382,902744,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/10,Other,,
1383,902745,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/10,Other,,
1384,902746,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/10,Other,,
1385,902883,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/9,Other,,
1386,902884,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/9,Other,,
1387,902885,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/9,Other,,
1388,902886,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/9,Other,,
1389,902887,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/9,Other,,
1390,902888,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/9,Other,,
1391,902889,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/9,Other,,
1392,902890,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/9,Other,,
1393,902891,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/9,Other,,
1394,902892,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/9,Other,,
1395,902893,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/9,Other,,
1396,902894,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/9,Other,,
1397,902895,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/9,Other,,
1398,902896,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/9,Other,,
1399,902897,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/9,Other,,
1400,902898,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/9,Other,,
1401,902899,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/9,Other,,
1402,902900,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/9,Other,,
1403,902901,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/9,Other,,
1404,902902,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/9,Other,,
1405,902903,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/10,Other,,
1406,902904,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/10,Other,,
1407,902905,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/10,Other,,
1408,902906,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/10,Other,,
1409,902907,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/10,Other,,
1410,902908,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/10,Other,,
1411,902909,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/10,Other,,
1412,902910,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/10,Other,,
1413,902911,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/10,Other,,
1414,903429,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/10,Other,,
1415,903430,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/10,Other,,
1416,903431,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/10,Other,,
1417,903432,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/10,Other,,
1418,903433,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/10,Other,,
1419,903434,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/10,Other,,
1420,903435,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/11,Other,,
1421,903436,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/11,Other,,
1422,903437,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/11,Other,,
1423,903438,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/11,Other,,
1424,903439,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/11,Other,,
1425,903440,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/11,Other,,
1426,903441,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/11,Other,,
1427,903442,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/11,Other,,
1428,903443,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/11,Other,,
1429,903444,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/11,Other,,
1430,903445,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/11,Other,,
1431,903446,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/11,Other,,
1432,903447,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/11,Other,,
1433,903448,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/11,Other,,
1434,903449,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/11,Other,,
1435,903450,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/11,Other,,
1436,903451,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/11,Other,,
1437,903452,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/11,Other,,
1438,903453,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/11,Other,,
1439,903454,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/11,Other,,
1440,903455,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/11,Other,,
1441,903456,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/12,Other,,
1442,903457,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/12,Other,,
1443,903458,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/12,Other,,
1444,903459,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/12,Other,,
1445,903460,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/12,Other,,
1446,903461,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/12,Other,,
1447,903462,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/12,Other,,
1448,903463,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/12,Other,,
1449,903464,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/12,Other,,
1450,903465,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/12,Other,,
1451,903466,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/12,Other,,
1452,903467,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/12,Other,,
1453,903468,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/12,Other,,
1454,903469,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/12,Other,,
1455,903470,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/12,Other,,
1456,903498,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/7,Other,,
1457,903499,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/7,Other,,
1458,903500,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/7,Other,,
1459,903501,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/7,Other,,
1460,903502,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/7,Other,,
1461,903503,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/7,Other,,
1462,903504,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/7,Other,,
1463,903505,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/7,Other,,
1464,903506,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/7,Other,,
1465,903507,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/7,Other,,
1466,903508,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/8,Other,,
1467,903509,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/8,Other,,
1468,903510,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/8,Other,,
1469,903511,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/8,Other,,
1470,903512,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/8,Other,,
1471,903513,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/8,Other,,
1472,903514,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/8,Other,,
1473,903515,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/8,Other,,
1474,903516,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/8,Other,,
1475,903517,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/8,Other,,
1476,903518,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/8,Other,,
1477,903519,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/8,Other,,
1478,904201,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/8,Other,,
1479,904202,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/8,Other,,
1480,904203,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/8,Other,,
1481,904204,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/8,Other,,
1482,904205,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/8,Other,,
1483,904206,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/8,Other,,
1484,904207,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/8,Other,,
1485,904208,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/8,Other,,
1486,904209,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/9,Other,,
1487,904210,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/9,Other,,
1488,904211,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/9,Other,,
1489,904212,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/9,Other,,
1490,904213,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/9,Other,,
1491,904214,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/9,Other,,
1492,904215,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/9,Other,,
1493,904216,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 366/9,Other,,
1494,904217,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 366/9,Other,,
1495,904218,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 366/9,Other,,
1496,904219,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/9,Other,,
1497,904220,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/9,Other,,
1498,904221,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/9,Other,,
1499,904222,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/9,Other,,
1500,904223,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/9,Other,,
1501,904224,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/9,Other,,
1502,904243,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/8,Other,,
1503,904260,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 366/16,Other,,
1504,904261,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 366/16,Other,,
1505,904262,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 366/16,Other,,
1506,904263,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 366/16,Other,,
1507,904264,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 366/16,Other,,
1508,904265,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 366/16,Other,,
1509,904266,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/16,Other,,
1510,904267,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/16,Other,,
1511,904268,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/16,Other,,
1512,904269,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/16,Other,,
1513,904270,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/16,Other,,
1514,906336,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/12,Other,,
1515,906337,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/12,Other,,
1516,906338,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/12,Other,,
1517,906339,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/12,Other,,
1518,906340,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/12,Other,,
1519,906341,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/12,Other,,
1520,906342,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/13,Other,,
1521,906343,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/13,Other,,
1522,906344,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/13,Other,,
1523,906345,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/13,Other,,
1524,906346,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/13,Other,,
1525,906347,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/13,Other,,
1526,906348,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/13,Other,,
1527,906349,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/13,Other,,
1528,906350,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/13,Other,,
1529,906351,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/13,Other,,
1530,906352,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/13,Other,,
1531,906353,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/13,Other,,
1532,906354,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/13,Other,,
1533,906355,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/13,Other,,
1534,906356,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/13,Other,,
1535,906357,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/13,Other,,
1536,906358,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 365/13,Other,,
1537,906359,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 365/13,Other,,
1538,906360,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 365/13,Other,,
1539,906361,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 365/13,Other,,
1540,906362,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 365/13,Other,,
1541,906363,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 365/14,Other,,
1542,906364,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 365/14,Other,,
1543,906365,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 365/14,Other,,
1544,906366,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 365/14,Other,,
1545,906367,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 365/14,Other,,
1546,906368,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 365/14,Other,,
1547,906369,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 365/14,Other,,
1548,906370,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 365/14,Other,,
1549,906371,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 365/14,Other,,
1550,906372,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 365/14,Other,,
1551,906373,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 365/14,Other,,
1552,906374,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 365/14,Other,,
1553,906375,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 365/14,Other,,
1554,906376,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 365/14,Other,,
1555,906377,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 365/14,Other,,
1556,906378,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 365/14,Other,,
1557,906412,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 366/9,Other,,
1558,906413,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 366/9,Other,,
1559,906414,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 366/9,Other,,
1560,906415,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 366/9,Other,,
1561,906416,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 366/9,Other,,
1562,906417,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 366/10,Other,,
1563,906418,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 366/10,Other,,
1564,906419,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 366/10,Other,,
1565,906420,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 366/10,Other,,
1566,906421,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 366/10,Other,,
1567,906422,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 366/10,Other,,
1568,906423,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 366/10,Other,,
1569,1035954,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/14,Other,,
1570,1035955,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/14,Other,,
1571,1035956,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/14,Other,,
1572,1035957,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/14,Other,,
1573,1035958,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/15,Other,,
1574,1035959,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/15,Other,,
1575,1035960,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/15,Other,,
1576,1035961,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/15,Other,,
1577,1035962,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/15,Other,,
1578,1035963,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/16,Other,,
1579,1036630,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/16,Other,,
1580,1036631,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/16,Other,,
1581,1036632,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/16,Other,,
1582,1036633,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/16,Other,,
1583,1039434,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/5,Other,,
1584,1039435,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/5,Other,,
1585,1039436,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/5,Other,,
1586,1039437,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/5,Other,,
1587,1039438,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/5,Other,,
1588,1039439,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/6,Other,,
1589,1039440,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/6,Other,,
1590,1039441,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/6,Other,,
1591,1039442,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/6,Other,,
1592,1039443,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/6,Other,,
1593,1039444,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/7,Other,,
1594,1039445,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/7,Other,,
1595,1039446,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/7,Other,,
1596,1041594,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/7,Other,,
1597,1041595,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/7,Other,,
1598,1041596,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/8,Other,,
1599,1041597,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/8,Other,,
1600,1041598,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/8,Other,,
1601,1041599,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/8,Other,,
1602,1041600,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/8,Other,,
1603,1041601,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/9,Other,,
1604,1041602,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/9,Other,,
1605,1041603,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/9,Other,,
1606,1041604,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/9,Other,,
1607,1041605,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/9,Other,,
1608,1041606,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/10,Other,,
1609,1041607,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/10,Other,,
1610,1041608,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/10,Other,,
1611,1041609,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/10,Other,,
1612,1041610,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/10,Other,,
1613,1041611,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/11,Other,,
1614,1041612,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/11,Other,,
1615,1041613,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/11,Other,,
1616,1041614,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/11,Other,,
1617,1041615,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/11,Other,,
1618,1041616,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/12,Other,,
1619,1041617,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/12,Other,,
1620,1041618,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/12,Other,,
1621,1041619,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/12,Other,,
1622,1042286,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/12,Other,,
1623,1042287,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/13,Other,,
1624,1042288,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/13,Other,,
1625,1042289,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/13,Other,,
1626,1042290,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/13,Other,,
1627,1042291,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/13,Other,,
1628,1042292,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/14,Other,,
1629,1042293,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/14,Other,,
1630,1042294,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/14,Other,,
1631,1042295,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/14,Other,,
1632,1042296,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/14,Other,,
1633,1042297,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/15,Other,,
1634,1042298,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/15,Other,,
1635,1042299,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/15,Other,,
1636,1042300,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/15,Other,,
1637,1042301,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/15,Other,,
1638,1042302,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 365/16,Other,,
1639,1042303,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 365/16,Other,,
1640,1042304,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 365/16,Other,,
1641,1042305,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 365/16,Other,,
1642,1042306,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 365/16,Other,,
1643,1044450,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/5,Other,,
1644,1044451,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/5,Other,,
1645,1044452,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/5,Other,,
1646,1044453,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/5,Other,,
1647,1044454,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/5,Other,,
1648,1044455,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/6,Other,,
1649,1044456,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/6,Other,,
1650,1044457,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/6,Other,,
1651,1044458,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/6,Other,,
1652,1044459,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/6,Other,,
1653,1044460,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/7,Other,,
1654,1044461,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/7,Other,,
1655,1044462,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/7,Other,,
1656,1044463,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/7,Other,,
1657,1044464,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/7,Other,,
1658,1044465,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/8,Other,,
1659,1044466,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/8,Other,,
1660,1045135,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/8,Other,,
1661,1045136,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/8,Other,,
1662,1045137,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/8,Other,,
1663,1045138,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/9,Other,,
1664,1045139,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/9,Other,,
1665,1045140,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/9,Other,,
1666,1045141,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/9,Other,,
1667,1045142,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/9,Other,,
1668,1045143,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/10,Other,,
1669,1045144,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/10,Other,,
1670,1045145,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/10,Other,,
1671,1045146,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/10,Other,,
1672,1045147,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/10,Other,,
1673,1045148,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/11,Other,,
1674,1045149,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/11,Other,,
1675,1045150,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/11,Other,,
1676,1045151,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/11,Other,,
1677,1045152,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/11,Other,,
1678,1045153,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/12,Other,,
1679,1045154,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/12,Other,,
1680,1045155,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/12,Other,,
1681,1045156,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/12,Other,,
1682,1045157,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/12,Other,,
1683,1045158,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/13,Other,,
1684,1045159,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 366/13,Other,,
1685,1045160,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 366/13,Other,,
1686,1045161,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 366/13,Other,,
1687,1045162,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 366/13,Other,,
1688,1045163,1,2,,103164240,3696,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 366/14,Other,,
1689,1054118,2,3,,103164240,3696,Active,400630.0,6532.0,0.0035,IC50,Binding affinity to SERT (unknown origin) by radioligand binding assay,Confirmatory,23919353.0,
1690,1054119,2,3,,103164240,3696,Active,543727.0,3356.0,0.22,IC50,Binding affinity to 5HT2A receptor (unknown origin) by radioligand binding assay,Confirmatory,23919353.0,
1691,1054120,2,3,,103164240,3696,Active,118206.0,1813.0,0.41,IC50,Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay,Confirmatory,23919353.0,
1692,1054121,2,3,,103164240,3696,Active,547645.0,3269.0,0.027000000000000003,IC50,Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay,Confirmatory,23919353.0,
1693,1054435,1,1,,103164240,3696,Active,,,,,"Antidepression-like activity in rat assessed as decrease in immobility time at 60 mg/kg, po by forced swimming test",Other,24139584.0,
1694,1071344,1,1,,103164240,3696,Unspecified,,,,,Permeability of the compound by BBB-PAMPA,Other,24389509.0,
1695,1079931,1,1,,103164240,3696,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1696,1079932,1,1,,103164240,3696,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1697,1079933,1,1,,103164240,3696,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1698,1079934,1,1,,103164240,3696,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1699,1079935,1,1,,103164240,3696,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1700,1079936,1,1,,103164240,3696,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1701,1079937,1,1,,103164240,3696,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1702,1079938,1,1,,103164240,3696,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1703,1079939,1,1,,103164240,3696,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1704,1079940,1,1,,103164240,3696,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1705,1079941,1,1,,103164240,3696,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1706,1079942,1,1,,103164240,3696,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1707,1079943,1,1,,103164240,3696,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1708,1079944,1,1,,103164240,3696,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1709,1079945,1,1,,103164240,3696,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1710,1079946,1,1,,103164240,3696,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1711,1079947,1,1,,103164240,3696,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1712,1079948,1,1,,103164240,3696,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1713,1079949,1,1,,103164240,3696,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1714,1086933,1,2,,103164240,3696,Unspecified,,,,,"Antidepressant activity in overnight fasted Mus musculus (mouse) assessed as decrease in immobility time at 10 mg/kg, ip administered 60 min prior to testing measured for 5 min by tail suspension test (Rvb = 169.8 +/- 13 secs)",Other,,
1715,1091955,1,2,,103164240,3696,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
1716,1091956,1,1,,103164240,3696,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
1717,1091957,1,1,,103164240,3696,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
1718,1091958,2,1,,103164240,3696,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
1719,1097336,1,3,,103164240,3696,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
1720,1114569,1,2,,103164240,3696,Active,,,,,"Antidepressant activity in albino Mus musculus (mouse) assessed as reduction in immobility time at 15 mg/kg, ip administered 30 min prior to testing by forced-swim test relative to control",Other,,
1721,1117298,1,2,,170464777,3696,Inactive,,,8.9125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1722,1117301,1,2,,170464777,3696,Active,,,11.2202,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
1723,1117302,1,2,,170464777,3696,Inactive,,,14.1254,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
1724,1117303,1,2,,170464777,3696,Inactive,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
1725,1117304,1,2,,170464777,3696,Active,,,11.2202,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1726,1117305,1,2,,170464777,3696,Active,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1727,1117308,1,1,,170464777,3696,Active,,,12.1866,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, ratio channel",Confirmatory,,
1728,1117309,1,1,,170464777,3696,Inactive,,,10.8613,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, blue channel",Confirmatory,,
1729,1117310,1,1,,170464777,3696,Inactive,,,8.912510000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1730,1117311,1,1,,170464777,3696,Inactive,,,11.2202,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
1731,1117312,1,1,,170464777,3696,Active,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1732,1117314,1,1,,170464777,3696,Inactive,,,11.2202,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1733,1117315,1,1,,170464777,3696,Inactive,,,14.1254,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
1734,1117316,1,1,,170464777,3696,Inactive,,,17.2141,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, green channel",Confirmatory,,
1735,1117318,1,1,,170464777,3696,Active,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
1736,1117326,1,1,,170464777,3696,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
1737,1117329,1,1,,170464777,3696,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
1738,1117336,1,1,,170464777,3696,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
1739,1117340,1,1,,170464777,3696,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
1740,1117341,1,1,,170464777,3696,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
1741,1117342,1,1,,170464777,3696,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
1742,1117343,1,1,,170464777,3696,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
1743,1117346,1,1,,170464777,3696,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
1744,1123529,1,1,,103164240,3696,Unspecified,,,,,Neuroleptic activity in po dosed rat assessed as concentration required to cause 50% reduction of motor activity,Other,37338.0,
1745,1123530,1,1,,103164240,3696,Unspecified,,,,,Neuroleptic activity in po dosed mouse assessed as inhibition of d-amphetamine sulfate-induced lethality administered for 0.5 hrs followed by d-amphetamine sulfate challenge measured after 24 hrs,Other,37338.0,
1746,1123532,1,1,,103164240,3696,Unspecified,,,,,Antidepressant activity in po dosed mouse assessed as inhibition of tetrabenazine hexamate-induced depression administered 1 hr followed by tetrabenazine hexamate challenge measured after 30 mins,Other,37338.0,
1747,1129361,1,1,,103164240,3696,Unspecified,,,,,Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis,Other,24601604.0,
1748,1129953,1,1,,103164240,3696,Unspecified,,,,,"Toxicity in Kunming mouse assessed as locomotor activity at 10 mg/kg, po measured for 10 mins (Rvb = 1165 +/- 263 cm)",Other,24618300.0,
1749,1131083,1,1,,103164240,3696,Unspecified,,,,,Antidepressant activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine methanesulfonate-induced reserpine like behavior administered 30 mins before tetrabenazine methanesulfonate challenge measured after 30 mins,Other,533882.0,
1750,1131104,1,1,,103164240,3696,Unspecified,,,,,"Antidepressant activity against reserpine-induced hypothermia CFLP mouse model assessed as change in esophageal temperature at 20 mg/kg, po treated before 2 to 24 hrs of reserpine challenge",Other,533885.0,
1751,1131106,1,1,,103164240,3696,Unspecified,,,,,Anticholinergic effect in sc dosed CFLP mouse assessed as inhibition of pilocarpine-induced salivation,Other,533885.0,
1752,1131107,1,1,,103164240,3696,Unspecified,,,,,Anticholinergic effect in sc dosed CFLP mouse assessed as inhibition of pilocarpine-induced mydriasis,Other,533885.0,
1753,1131108,1,2,,103164240,3696,Active,,,0.00126,Kd,Anticholinergic effect in guinea pig ileum assessed as inhibition of acetylcholine-induced contraction,Confirmatory,533885.0,
1754,1132844,1,1,,103164240,3696,Unspecified,,,,,"Analgesic activity in mouse assessed as inhibition of acetic acid-induced writhing response at 30 mg/kg, po administered 30 mins prior to acetic acid-challenge relative to control",Other,671457.0,
1755,1132845,1,1,,103164240,3696,Inconclusive,,,,,Analgesic activity in mouse by hot-plate test,Other,671457.0,
1756,1132846,1,1,,103164240,3696,Unspecified,,,,,Antidepressant activity in mouse assessed as reversal of reserpine-induced hypothermia measured as cumulative temperature rise at 30 mg/kg administered 17 hrs post reserpine-challenge,Other,671457.0,
1757,1134043,1,1,,103164240,3696,Unspecified,,,,,Antitetrabenazine activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine-induced ptosis challenged with tetrabenazine after 30 mins later and after another 30 mins of drug treatment,Other,850252.0,
1758,1144364,1,1,,103164240,3696,Inactive,,,,,"Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 5 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge",Other,1246052.0,
1759,1144365,1,1,,103164240,3696,Active,,,,,"Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 10 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge",Other,1246052.0,
1760,1144366,1,1,,103164240,3696,Active,,,,,"Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 20 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge",Other,1246052.0,
1761,1144367,1,1,,103164240,3696,Active,,,,,"Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 25 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge",Other,1246052.0,
1762,1144368,1,1,,103164240,3696,Active,,,,,"Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 100 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge",Other,1246052.0,
1763,1144378,1,1,,103164240,3696,Unspecified,,,,,"Antipsychotic activity in mouse assessed as change in methamphetamine-induced hyperactivity at 10 mg/kg, po relative to control",Other,1246052.0,
1764,1144379,1,1,,103164240,3696,Unspecified,,,,,"Antipsychotic activity in mouse assessed as change in methamphetamine-induced hyperactivity at 20 mg/kg, po relative to control",Other,1246052.0,
1765,1144381,1,1,,103164240,3696,Inactive,,,,,"Antipsychotic activity in mouse assessed as change in methamphetamine-induced hyperactivity at 5 mg/kg, po relative to control",Other,1246052.0,
1766,1144413,1,1,,103164240,3696,Unspecified,,,,,Antidepressant activity in po dosed Swiss mouse assessed as reversal of reserpine-induced ptosis administered 1 hr prior to reserpine challenge,Other,1249800.0,
1767,1144414,1,1,,103164240,3696,Unspecified,,,,,Antidepressant activity in po dosed Swiss mouse assessed as reversal of reserpine-induced hypothermia measured over 5 hrs,Other,1249800.0,
1768,1144415,1,2,,103164240,3696,Unspecified,,,,,Antispasmodic activity in guinea pig ileum assessed as inhibition of acetylcholine-induced spasm,Other,1249800.0,
1769,1144416,1,2,,103164240,3696,Unspecified,,,,,Antispasmodic activity in guinea pig ileum assessed as inhibition of histamine-induced spasm,Other,1249800.0,
1770,1144417,1,1,,103164240,3696,Unspecified,,,,,Acute toxicity in po dosed Swiss mouse assessed as mortality after 7 days,Other,1249800.0,
1771,1144418,1,1,,103164240,3696,Unspecified,,,,,Toxicity in po dosed Swiss mouse assessed as behavioral changes,Other,1249800.0,
1772,1144419,1,1,,103164240,3696,Unspecified,,,,,Toxicity in po dosed Swiss mouse assessed as clonic convulsion,Other,1249800.0,
1773,1147085,1,1,,103164240,3696,Active,,,,,"Antidepressant activity in Swiss-Webster mouse assessed as prevention of reserpine-induced ptosis at 10 to 50 mg/kg, ip",Other,403284.0,
1774,1147092,1,1,,103164240,3696,Inactive,,,,,"Antipsychotic activity in Sprague-Dawley rat assessed as prevention of d-amphetamine-induced stereotyped behavior at 32 mg/kg, po measured for 1 min after 90, 100, and 110 mins injection of amphetamine",Other,403284.0,
1775,1150604,1,1,,103164240,3696,Unspecified,,,,,Acute toxicity in ip dosed albino mouse assessed as mortality measured for 5 days,Other,950648.0,
1776,1150605,1,1,,103164240,3696,Unspecified,,,,,Antidepressant activity in ip dosed mouse assessed as prevention of reserpine-induced ptosis,Other,950648.0,
1777,1150606,1,1,,103164240,3696,Unspecified,,,,,Antidepressant activity in ip dosed rat assessed as prevention of tetrabenazine-induced ptosis,Other,950648.0,
1778,1152645,1,3,,103164240,3696,Active,400630.0,6532.0,,IC50,Displacement of [3H]imipramine from human recombinant SERT expressed in CHO cells,Confirmatory,24805037.0,
1779,1159386,1,2,,103164240,3696,Unspecified,,,,,ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
1780,1159387,1,2,,103164240,3696,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
1781,1159389,1,2,,103164240,3696,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
1782,1159390,1,2,,103164240,3696,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
1783,1159391,1,2,,103164240,3696,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
1784,1159394,1,2,,103164240,3696,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
1785,1159395,1,2,,103164240,3696,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
1786,1159396,1,2,,103164240,3696,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
1787,1159509,1,1,,170464777,3696,Inconclusive,119626539.0,4790.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1788,1159515,1,1,,170464777,3696,Inconclusive,,,18.9959,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1789,1159516,1,1,,170464777,3696,Inconclusive,119611100.0,22926.0,0.3011,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1790,1159517,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1791,1159518,1,1,,170464777,3696,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1792,1159519,1,1,,170464777,3696,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1793,1159520,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1794,1159521,1,1,,170464777,3696,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1795,1159523,1,1,,170464777,3696,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1796,1159525,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1797,1159526,1,1,,170464777,3696,Inconclusive,119627033.0,3725.0,4.2527,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1798,1159527,1,1,,170464777,3696,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1799,1159528,1,1,,170464777,3696,Active,119627033.0,3725.0,12.9418,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1800,1159529,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1801,1159531,1,1,,170464777,3696,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1802,1159551,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1803,1159552,1,1,,170464777,3696,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1804,1159553,2,1,,170464777,3696,Inactive,325495463.0,5914.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1805,1159555,1,1,,170464777,3696,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1806,1159580,2,1,,268734581,3696,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1807,1159580,2,1,,273002864,3696,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1808,1159607,2,1,,312309767,3696,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1809,1159614,1,2,,170464777,3696,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1810,1161578,1,1,,103164240,3696,Unspecified,,,,,Permeability of the compound by PAMPA-BBB assay,Other,25156301.0,
1811,1171393,1,2,,103164240,3696,Unspecified,,,,,Oxidative metabolism in human liver microsomes assessed as protein covalent binding measured per mg protein at 10 uM after 1 hr in presence of NADPH,Other,25408839.0,
1812,1172091,1,1,,103164240,3696,Active,,,,,"Antidepressant-like activity in mouse assessed as reduction in immobility time at 10 to 20 mg/kg, ip dosed 60 mins before test by forced swim test",Other,25435254.0,
1813,1172092,1,1,,103164240,3696,Unspecified,,,,,Effect on spontaneous locomotor activity in ip dosed mouse during 2 to 6 mins,Other,25435254.0,
1814,1173449,1,1,,103164240,3696,Unspecified,,,,,Effective permeability of the compound by PAMPA assay,Other,25454267.0,
1815,1175702,1,1,,103164240,3696,Active,,,,,"Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 0.5 mg/kg, ip measured for 5 mins by tail suspension test relative to control",Other,25488839.0,
1816,1183278,1,1,,103164240,3696,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25016233.0,
1817,1192730,1,1,,103164240,3696,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25614117.0,
1818,1192731,1,1,,103164240,3696,Unspecified,,,,,Permeability of the compound in PBS/EtOH buffer at 100 ug/ml by PAMPA,Other,25614117.0,
1819,1195628,1,1,,103164240,3696,Active,,,,,"Antidepressant-like activity in mouse assessed as decrease in immobility time at 10 mg/kg, po by forced swimming test",Other,25900218.0,
1820,1196338,1,2,,103164240,3696,Active,400630.0,6532.0,0.0021,Ki,Displacement of [3H]imipramine from human SERT expressed in CHO cells,Confirmatory,25557493.0,
1821,1207159,1,1,,103164240,3696,Active,,,3.6,IC50,Inhibition of Na channel (species unknown),Confirmatory,21300721.0,
1822,1207188,1,1,,103164240,3696,Active,,,8.3,IC50,Inhibition of voltage-gated L-type Ca channel (species unknown),Confirmatory,21300721.0,
1823,1207218,1,1,,103164240,3696,Active,,,3.4,IC50,Inhibition of hERG K channel,Confirmatory,21300721.0,
1824,1207249,1,2,,103164240,3696,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
1825,1207659,1,2,,103164240,3696,Active,116412.0,24239.0,4.05,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes,Confirmatory,22761000.0,
1826,1207660,1,2,,103164240,3696,Active,116412.0,24239.0,8.3,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes,Confirmatory,22761000.0,
1827,1209241,1,2,,103164240,3696,Unspecified,116241312.0,1576.0,,,Drug metabolism in assessed as human CYP3A4-mediated intrinsic clearance per mg protein,Other,22942316.0,
1828,1209242,1,2,,103164240,3696,Unspecified,116241312.0,1576.0,,,Drug metabolism in assessed as human CYP3A4-mediated maximum rate of reaction per mg protein,Other,22942316.0,
1829,1209243,1,2,,103164240,3696,Active,116241312.0,1576.0,5.0,Km,Drug metabolism in assessed as human CYP3A4-mediated metabolism,Confirmatory,22942316.0,
1830,1209246,1,2,,103164240,3696,Unspecified,60416369.0,1557.0,,,Drug metabolism in assessed as human CYP2C19-mediated maximum rate of reaction per mg protein,Other,22942316.0,
1831,1209247,1,2,,103164240,3696,Unspecified,,,,,Drug metabolism in human liver microsomes assessed as intrinsic clearance per mg protein by multiple depletion curves method,Other,22942316.0,
1832,1209248,1,2,,103164240,3696,Unspecified,,,,,Drug metabolism in human liver microsomes assessed as intrinsic clearance per mg protein by optimal design approach,Other,22942316.0,
1833,1209250,1,2,,103164240,3696,Active,,,14.2,Km,Drug metabolism in human liver microsomes by multiple depletion curves method,Confirmatory,22942316.0,
1834,1209251,1,2,,103164240,3696,Active,,,14.3,Km,Drug metabolism in human liver microsomes by optimal design approach,Confirmatory,22942316.0,
1835,1209252,1,2,,103164240,3696,Active,60416369.0,1557.0,5.0,Km,Drug metabolism in assessed as human CYP2C19-mediated metabolism,Confirmatory,22942316.0,
1836,1209253,1,2,,103164240,3696,Active,117144.0,1544.0,5.0,Km,Drug metabolism in assessed as human CYP1A2-mediated metabolism,Confirmatory,22942316.0,
1837,1209254,1,2,,103164240,3696,Unspecified,60416369.0,1557.0,,,Drug metabolism in assessed as human CYP2C19-mediated intrinsic clearance per mg protein,Other,22942316.0,
1838,1209255,1,2,,103164240,3696,Unspecified,117144.0,1544.0,,,Drug metabolism in assessed as human CYP1A2-mediated intrinsic clearance per mg protein,Other,22942316.0,
1839,1209256,1,2,,103164240,3696,Unspecified,117144.0,1544.0,,,Drug metabolism in assessed as human CYP1A2-mediated maximum rate of reaction per mg protein,Other,22942316.0,
1840,1209258,1,2,,103164240,3696,Unspecified,,,,,Drug metabolism in human liver microsomes assessed as maximum rate of reaction per mg protein by multiple depletion curves method,Other,22942316.0,
1841,1209259,1,2,,103164240,3696,Unspecified,,,,,Drug metabolism in human liver microsomes assessed as maximum rate of reaction per mg protein by optimal design approach,Other,22942316.0,
1842,1210069,1,2,,103164240,3696,Unspecified,21264413.0,1573.0,50.0,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
1843,1211293,1,2,,103164240,3696,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
1844,1211294,1,1,,103164240,3696,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
1845,1211295,1,1,,103164240,3696,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
1846,1211296,1,2,,103164240,3696,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
1847,1211297,1,1,,103164240,3696,Unspecified,,,,,Drug recovery in plasma (unknown origin),Other,21098647.0,
1848,1211298,1,1,,103164240,3696,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21098647.0,
1849,1211791,1,1,,103164240,3696,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
1850,1211792,1,1,,103164240,3696,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
1851,1211793,1,1,,103164240,3696,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,21998403.0,
1852,1211794,1,2,,103164240,3696,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
1853,1211795,1,1,,103164240,3696,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21998403.0,
1854,1211796,1,1,,103164240,3696,Unspecified,,,,,Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
1855,1211797,1,1,,103164240,3696,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
1856,1211798,1,1,,103164240,3696,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
1857,1212314,1,1,,103164240,3696,Unspecified,,,260.0,IC50,Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins,Confirmatory,23378628.0,
1858,1212316,1,1,,103164240,3696,Unspecified,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning measured per 10'6 cells at 1 uM after 5 mins by LC-MS analysis,Other,23378628.0,
1859,1212317,1,1,,103164240,3696,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning measured per 10'6 cells at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride,Other,23378628.0,
1860,1212318,1,1,,103164240,3696,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM up to 10 mins by LC-MS analysis,Other,23378628.0,
1861,1212319,1,1,,103164240,3696,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM measured at 10 mins by LC-MS analysis in presence of ammonium chloride,Other,23378628.0,
1862,1212325,1,1,,103164240,3696,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride,Other,23378628.0,
1863,1212326,1,1,,103164240,3696,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of nigericin and monensin,Other,23378628.0,
1864,1212327,1,1,,103164240,3696,Inactive,,,,,"Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride, nigericin and monensin",Other,23378628.0,
1865,1212328,1,1,,103164240,3696,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of astemizole,Other,23378628.0,
1866,1212329,1,1,,103164240,3696,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of dextromethorphan,Other,23378628.0,
1867,1212330,1,1,,103164240,3696,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of chloroquine,Other,23378628.0,
1868,1212332,1,1,,103164240,3696,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of propranolol,Other,23378628.0,
1869,1212333,1,1,,103164240,3696,Active,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of diclofenac,Other,23378628.0,
1870,1212334,1,1,,103164240,3696,Active,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of rifampin,Other,23378628.0,
1871,1212335,1,1,,103164240,3696,Active,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of atorvastatin,Other,23378628.0,
1872,1212341,1,1,,103164240,3696,Unspecified,,,,,Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay,Other,23378628.0,
1873,1217704,1,2,,103164240,3696,Unspecified,117144.0,1544.0,,,Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1874,1217705,1,2,,103164240,3696,Unspecified,117205.0,1555.0,,,Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1875,1217706,1,2,,103164240,3696,Unspecified,6686268.0,1559.0,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1876,1217707,1,2,,103164240,3696,Unspecified,60416369.0,1557.0,,,Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system,Other,21467212.0,
1877,1217708,1,2,,103164240,3696,Unspecified,84028191.0,1565.0,,,Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1878,1217709,1,2,,103164240,3696,Unspecified,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1879,1217710,1,2,,103164240,3696,Unspecified,,,,,Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting,Other,21467212.0,
1880,1217711,1,2,,103164240,3696,Unspecified,,,,,Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
1881,1217712,1,2,,103164240,3696,Unspecified,117225.0,1558.0,,,Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1882,1217727,1,2,,103164240,3696,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
1883,1217728,1,1,,103164240,3696,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay,Other,21467212.0,
1884,1217729,1,1,,103164240,3696,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation,Other,21467212.0,
1885,1222793,1,1,,103164240,3696,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
1886,1223488,1,1,,103164240,3696,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4",Other,22096083.0,
1887,1223490,1,1,,103164240,3696,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells,Other,22096083.0,
1888,1224817,1,1,,442469,3696,Inactive,,,,,Assays to identify small molecules inhibitory for eIF4E expression,Other,26144883.0,
1889,1224834,3,1,,170464777,3696,Inconclusive,,,37.578,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1890,1224835,1,1,,170464777,3696,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1891,1224836,1,1,,170464777,3696,Inconclusive,,,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1892,1224837,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1893,1224838,1,1,,170464777,3696,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1894,1224839,1,1,,170464777,3696,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1895,1224840,3,1,,170464777,3696,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1896,1224841,3,1,,170464777,3696,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1897,1224842,3,1,,170464777,3696,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1898,1224843,1,1,,170464777,3696,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1899,1224844,1,1,,170464777,3696,Inconclusive,,,16.9301,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1900,1224845,1,1,,170464777,3696,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1901,1224846,1,1,,170464777,3696,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1902,1224847,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1903,1224848,3,1,,170464777,3696,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1904,1224849,3,1,,170464777,3696,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1905,1224857,2,1,,170464777,3696,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1906,1224859,2,1,,90341377,3696,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1907,1224859,2,1,,170464777,3696,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1908,1224863,1,1,,176484038,3696,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1909,1224863,1,1,,316920365,3696,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1910,1224867,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1911,1224868,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1912,1224869,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1913,1224870,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1914,1224871,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1915,1224872,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1916,1224873,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1917,1224874,1,1,,170464777,3696,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1918,1224875,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1919,1224876,1,1,,170464777,3696,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1920,1224877,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1921,1224878,1,1,,170464777,3696,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1922,1224879,1,1,,170464777,3696,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1923,1224880,1,1,,170464777,3696,Inconclusive,,,15.089,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1924,1224881,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1925,1224882,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1926,1224883,1,1,,170464777,3696,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1927,1224884,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1928,1224885,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1929,1224886,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1930,1224887,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1931,1224888,1,1,,170464777,3696,Inconclusive,,,3.378,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1932,1224889,1,1,,170464777,3696,Inconclusive,,,15.089,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1933,1224890,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1934,1224892,1,1,,170464777,3696,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1935,1224893,1,1,,170464777,3696,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1936,1224894,1,1,,170464777,3696,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1937,1224895,1,1,,170464777,3696,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1938,1224896,1,1,,170464777,3696,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1939,1224905,2,1,,92308804,3696,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1940,1224905,2,1,,92308804,3696,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1941,1255968,1,1,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as immobility at 10 mg/kg, po administered 60 mins before test measured for 6 mins by forced swimming test relative to control",Other,26428872.0,
1942,1255970,1,1,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time at 10 mg/kg, po administered 60 mins before test measured for 6 mins by forced swimming test relative to control",Other,26428872.0,
1943,1255972,1,1,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as immobility at 10 mg/kg, po administered 60 mins before test measured for 6 mins by tail suspension test relative to control",Other,26428872.0,
1944,1255974,1,1,,103164240,3696,Unspecified,,,,,"Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time at 10 mg/kg, po administered 60 mins before test measured for 6 mins by tail suspension test relative to control",Other,26428872.0,
1945,1259241,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1946,1259242,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1947,1259243,1,1,,170464777,3696,Inconclusive,124375976.0,367.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1948,1259244,1,1,,170464777,3696,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1949,1259247,1,1,,170464777,3696,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1950,1259248,1,1,,170464777,3696,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1951,1259325,1,2,,336954347,3696,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1952,1259344,1,1,,144203725,3696,Inconclusive,,,14.1254,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1953,1259355,1,1,,26751600,3696,Inconclusive,,,35.4813,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1954,1259356,1,1,,144203725,3696,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1955,1259364,1,1,,170464777,3696,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1956,1259365,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1957,1259366,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1958,1259367,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1959,1259368,1,1,,170464777,3696,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1960,1259369,1,1,,170464777,3696,Active,109731339.0,2737.0,4.7308,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1961,1259377,1,1,,170464777,3696,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1962,1259378,1,1,,170464777,3696,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1963,1259379,1,1,,170464777,3696,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1964,1259380,1,1,,170464777,3696,Active,,,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1965,1259381,1,1,,170464777,3696,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1966,1259382,1,1,,170464777,3696,Active,,,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1967,1259383,1,1,,170464777,3696,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1968,1259384,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1969,1259385,1,1,,170464777,3696,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1970,1259386,1,1,,170464777,3696,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1971,1259387,1,1,,170464777,3696,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1972,1259388,1,1,,170464777,3696,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1973,1259390,1,1,,170464777,3696,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1974,1259391,1,1,,170464777,3696,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1975,1259392,1,1,,170464777,3696,Active,109731339.0,2737.0,7.4978,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1976,1259393,1,1,,170464777,3696,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1977,1259394,1,1,,170464777,3696,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1978,1259395,1,1,,170464777,3696,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1979,1259396,1,1,,170464777,3696,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1980,1259400,1,1,,170464777,3696,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1981,1259401,1,1,,170464777,3696,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1982,1259402,1,1,,170464777,3696,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1983,1259403,1,1,,170464777,3696,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1984,1259404,1,1,,170464777,3696,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1985,1259407,1,1,,363907120,3696,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1986,1259408,1,1,,363894762,3696,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
1987,1259416,1,2,,340080063,3696,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1988,1259416,1,2,,375177864,3696,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1989,1259421,1,1,,340080063,3696,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1990,1259421,1,1,,375177864,3696,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1991,1259423,1,2,,354795901,3696,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1992,1259423,1,2,,354807217,3696,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1993,1259423,1,2,,354927264,3696,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1994,1259423,1,2,,355020466,3696,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
